Antibiotic therapy for pelvic inflammatory disease by Savaris, Ricardo F et al.
Cochrane Database of Systematic Reviews
Antibiotic therapy for pelvic inflammatory disease (Review)
Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross J
Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross J.
Antibiotic therapy for pelvic inflammatory disease.
Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD010285.
DOI: 10.1002/14651858.CD010285.pub2.
www.cochranelibrary.com
Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
16RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
27ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
35DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
106DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
107CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
107DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
108SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
108DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
109NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAntibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antibiotic therapy for pelvic inflammatory disease
Ricardo F Savaris1, Daniele G Fuhrich1, Rui V Duarte2, Sebastian Franik3 , Jonathan Ross4
1Ginecologia e Obstetricia, UFRGS-FAMED, Porto Alegre, Brazil. 2Liverpool Reviews and Implementation Group, University of
Liverpool, Liverpool, UK. 3Faculty of Medical School, Radboud University Nijmegen, Nijmegen, Netherlands. 4Department of G U
Medicine, The Whittall Street Clinic, Birmingham, UK
Contact address: Ricardo F Savaris, Ginecologia e Obstetricia, UFRGS-FAMED, Ramiro Barcelos 2350/1124, Porto Alegre, RS,
90035-903, Brazil. rsavaris@hcpa.edu.br, ricardosavaris@gmail.com.
Editorial group: Cochrane STI Group.
Publication status and date: New, published in Issue 4, 2017.
Citation: Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database
of Systematic Reviews 2017, Issue 4. Art. No.: CD010285. DOI: 10.1002/14651858.CD010285.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Pelvic inflammatory disease (PID) is an infection that affects 4% to 12% of young women, and is one of the most common causes
of morbidity in this age group. The main intervention for acute PID is the use of broad-spectrum antibiotics which cover Chlamydia
trachomatis, Neisseria gonorrhoeae, and anaerobic bacteria, administered intravenously, intramuscularly, or orally. In this review, we
assessed the optimal treatment regimen for PID.
Objectives
To assess the effectiveness and safety of antibiotic regimens used to treat pelvic inflammatory disease.
Search methods
We searched the Cochrane Sexually Transmitted Infections Review Group’s Specialized Register, which included randomized controlled
trials (RCTs) from 1944 to 2016, located through electronic searching and handsearching; the Cochrane Central Register of Controlled
Trials (CENTRAL), Ovid platform (1991 to July 2016); MEDLINE (1946 to July 2016); Embase (1947 to July 2016); LILACS,
iAHx interface (1982 to July 2016); World Health Organization International Clinical Trials Registry Platform (July 2016); Web of
Science (2001 to July 2016); OpenGrey (1990, 1992, 1995, 1996, and 1997); and abstracts in selected publications.
Selection criteria
We included RCTs comparing the use of antibiotics with placebo or other antibiotics for the treatment of PID in women of reproductive
age, either as inpatient or outpatient treatment. We limited our review to comparison of drugs in current use that are recommended
for consideration by the 2015 US Centers for Disease Control and Prevention (CDC) guidelines for treatment of PID.
Data collection and analysis
At least two review authors independently selected trials for inclusion, extracted data, and assessed risk of bias.We contacted investigators
to obtain missing information. We resolved disagreements by consensus or by consulting a fourth review author if necessary.We assessed
the quality of the evidence using GRADE criteria, classifying it as high, moderate, low, or very low. We calculated Mantel-Haenszel
risk ratios (RR), using either random-effects or fixed-effect models and number needed to treat for an additional beneficial outcome or
for an additional harmful outcome, with their 95% confidence interval (CI), to measure the effect of the treatments. We conducted
sensitivity analyses limited to studies at low risk of bias, for comparisons where such studies were available.
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Main results
We included 37 RCTs (6348 women). The quality of the evidence ranged from very low to high, the main limitations being serious
risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency, and serious imprecision.
Azithromycin versus doxycycline
There was no clear evidence of a difference between the two drugs in rates of cure for mild-moderate PID (RR 1.18, 95% CI 0.89 to
1.55, I2 = 72%, 2 RCTs, 243 women, very low-quality evidence), severe PID (RR 1.00, 95% CI 0.96 to 1.05, 1 RCT, 309 women, low-
quality evidence), or adverse effects leading to discontinuation of treatment (RR 0.71, 95% CI 0.38 to 1.34, 3 RCTs, 552 women, I2 =
0%, low-quality evidence). In a sensitivity analysis limited to a single study at low risk of bias, azithromycin was superior to doxycycline
in achieving cure in mild-moderate PID (RR 1.35, 95% CI 1.10 to 1.67, 133 women, moderate-quality evidence).
Quinolone versus cephalosporin
There was no clear evidence of a difference between the two drugs in rates of cure for mild-moderate PID (RR 1.04, 95% CI 0.98 to
1.10, 3 RCTs, 459 women, I2 = 5%, low-quality evidence), severe PID (RR 1.06, 95% CI 0.91 to 1.23, 2 RCTs, 313 women, I2 =
7%, low-quality evidence), or adverse effects leading to discontinuation of treatment (RR 2.24, 95% CI 0.52 to 9.72, 5 RCTs, 772
women, I2 = 0%, very low-quality evidence).
Nitroimidazole versus no use of nitroimidazole
There was no conclusive evidence of a difference between the nitroimidazoles (metronidazole) group and the group receiving other
drugs with activity over anaerobes (e.g. amoxicillin-clavulanate) in rates of cure for mild-moderate PID (RR 1.01, 95% CI 0.93 to
1.10, 5 RCTs, 2427 women, I2 = 60%, moderate-quality evidence), severe PID (RR 0.96, 95% CI 0.92 to 1.01, 11 RCTs, 1383
women, I2 = 0%, moderate-quality evidence), or adverse effects leading to discontinuation of treatment (RR 1.00, 95% CI 0.63 to
1.59; participants = 3788; studies = 16; I2 = 0% , low-quality evidence). In a sensitivity analysis limited to studies at low risk of bias,
findings did not differ substantially from the main analysis (RR 1.06, 95% CI 0.98 to 1.15, 2 RCTs, 1201 women, I2 = 32%, high-
quality evidence).
Clindamycin plus aminoglycoside versus quinolone
There was no evidence of a difference between the two groups in rates of cure for mild-moderate PID (RR 0.88, 95% CI 0.69 to 1.13,
1 RCT, 25 women, very low-quality evidence), severe PID (RR 1.02, 95% CI 0.87 to 1.19, 2 studies, 151 women, I2 = 0%, low-quality
evidence), or adverse effects leading to discontinuation of treatment (RR 0.21, 95% CI 0.02 to 1.72, 3 RCTs, 163 women, very low-
quality evidence).
Clindamycin plus aminoglycoside versus cephalosporin
There was no clear evidence of a difference between the two groups in rates of cure for mild-moderate PID (RR 1.02, 95% CI 0.95
to 1.09, 2 RCTs, 150 women, I2 = 0%, low-quality evidence), severe PID (RR 1.00, 95% CI 0.95 to 1.06, 10 RCTs, 959 women, I
2 = 21%, moderate-quality evidence), or adverse effects leading to discontinuation of treatment (RR 0.78, 95% CI 0.18 to 3.42, 10
RCTs, 1172 women, I2 = 0%, very low-quality evidence).
Authors’ conclusions
We found no conclusive evidence that one regimen of antibiotics was safer or more effective than any other for the cure of PID, and
there was no clear evidence for the use of nitroimidazoles (metronidazole) compared to use of other drugs with activity over anaerobes.
Moderate-quality evidence from a single study at low risk of bias suggested that a macrolide (azithromycin) may be more effective than a
tetracycline (doxycycline) for curing mild-moderate PID. Our review considered only the drugs that are currently used and mentioned
by the CDC.
P L A I N L A N G U A G E S U M M A R Y
Treatment for pelvic inflammatory disease
Review question
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We assessed the effectiveness and safety of different treatments for pelvic inflammatory disease (PID) that are recommended for
consideration by current clinical guidelines for treatment of PID (the 2015 US Centers for Disease Control and Prevention guidelines
for treatment of PID).
Background
PID is an infection of the upper part of the woman’s reproductive system (womb, fallopian tubes (tube connecting the womb and
ovary that the egg travels along), ovaries (which make eggs), and inside of the pelvis). It is a common condition affecting women of
childbearing age. Symptoms of PID vary, ranging from no symptoms to severe symptoms. If effective treatment is not started promptly,
the consequences of the condition can be infertility (unable to have children), pregnancies outside of the womb, and chronic pelvic
pain (pain in the lower tummy). There is a wide range of treatment options, the choice of which is based on severity of symptoms,
experience of the doctor, national/international guidelines, and rate of side effects. We wanted to learn if there is a better antibiotic
(used to treat bacterial infections) therapy with higher rates of cure and lower side effects to treat PID.
Trial characteristics
We searched the available literature up to 11 July 2016 and included 37 studies with 6348 women with an average of 14 days of
treatment and follow-up (monitoring after treatment). These trials included women of childbearing age with mild to severe PID. Trials
mostly used a combination of antibiotics with different administration routes: intravenous (into a blood vessel), intramuscular (into
the muscle), and oral (as a tablet). In mild-moderate cases, intramuscular and oral treatments were prescribed, and in moderate-severe
cases, treatments were usually started in hospital and were completed at home.
Key results
We found no conclusive evidence that one treatment was safer or more effective than any other for the cure of PID, and there was
no clear evidence for the use of nitroimidazoles (a type of antibiotic; metronidazole) compared to use of other antibiotics. Moderate-
quality evidence from a single study at low risk of bias suggested that a macrolide (a type of antibiotic; azithromycin) may be more
effective than a tetracycline (a type of antibiotic; doxycycline) for curing mild-moderate PID.
Quality of evidence
The quality of the evidence ranged from very low to high, themain problems being serious risk of bias (poor reporting of study methods;
doctors and women may have known which medicine was given), and results differed across studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Azithromycin compared to doxycycline for pelvic inflammatory disease (PID)
Population: women with PID
Setting: hospital ward or outpat ient clinic
Intervention: azithromycin
Comparison: doxycycline
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of women
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with doxycycline Risk with azithromycin
Clinical cure according
to criteria established
by study authors
M ild-moderate PID
Follow-up: median 14
days
84/ 122
750 per 1000
99/ 121
818 per 1000
(740 to 876)
RR 1.18
(0.89 to 1.55)
NNTB 13
to
NNTH 3
243
(2 RCTs)
⊕©©©
Very low 1,2,3
-
Clinical cure according
to criteria established
by study authors
M ild-moderate PID
Follow-up: median 14
days
Sensit ivity analysis re-
stricted to study at low
risk of bias
42/ 67
627 per 1000
56/ 66
848 per 1000
(743 to 921)
RR 1.35
(1.10 to 1.67)
NNTB 5
(3 to 14)
133
(1 RCT)
⊕⊕⊕©
M oderate5
-
Clinical cure according
to criteria established
by study authors
Severe PID
Follow-up: range 13-18
days
93/ 96
969 per 1000
207/ 213
971 per 1000
(940 to 987)
RR 1.00
(0.96 to 1.05)
NNTB 16
to
NNTH 29
309
(1 RCT)
⊕⊕©©
Low 4
-
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Adverse events: any
ant ibiot ic-related ad-
verse event leading to
discont inuat ion of ther-
apy
Follow-up: range 13-18
days
17/ 217
78 per 1000
16/ 335
47 per 1000
(29 to 76)
RR 0.71
(0.38 to 1.34)
NNTB 13
to
NNTH 101
552
(3 RCTs)
⊕⊕©©
Low 1,3
-
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; PID: pelvic
inf lammatory disease; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for serious risk of bias (poor report ing of methods and high risk of performance and detect ion bias in
one or more studies).
2 Downgraded one level for serious inconsistency (I2 = 72%).
3 Downgraded one level for serious imprecision: conf idence intervals compatible with benef it in one or both groups, or with
no dif ference between the groups.
4 Downgraded two levels for very serious risk of bias: single unblinded study with poor report ing of methods.
5 Downgraded one level for serious imprecision: single study with only 98 events.
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B A C K G R O U N D
Description of the condition
Pelvic inflammatory disease (PID) in women describes inflamma-
tion of the upper genital tract and surrounding structures as a re-
sult of ascending infection from the lower genital tract - bacteria
spread directly from the cervix to the endometrium and on to
the upper genital tract (Soper 2010). The signs and symptoms of
PID are not specific and may range from asymptomatic to serious
illness. PID can produce endometritis, parametritis (infection of
the structures near the uterus), salpingitis (infection of the fallop-
ian tubes), oophoritis (infection of the ovary), and tubo-ovarian
abscess (Workowski 2015). Peritonitis (infection inside the peri-
toneum, the thin layer of tissue lining the abdomen) and perihep-
atitis (infection around the liver) can also occur. Peritonitis, tubo-
ovarian abscess, and severe systemic illness (e.g. fever and malaise)
are considered severe forms of PID; the other forms of presenta-
tion are considered mild or moderate according to the subjective
opinion of the examining doctor or nurse (Soper 2010).
The most common complaint of PID is lower abdominal pain,
with or without vaginal discharge. Specific grading of the clin-
ical presentation using symptom scores has been described (e.g.
McCormack 1977; Hager 1989), but has not been validated, and
use of these scores is inconsistent. PID does not have a diagnostic
gold standard. The most commonly used diagnostic criteria are
based on those from the Centers for Disease Control and Pre-
vention (CDC) (Workowski 2015), namely sexually active young
women and other women at risk for sexually transmitted disease
(STD)who are experiencing recent pelvic or lower abdominal pain
where no cause other than PID can be identified, and one or more
of the following minimum criteria are present on pelvic exami-
nation: cervical motion tenderness, uterine tenderness, or adnexal
tenderness. The requirement for all three minimum criteria to be
present increases the specificity of the diagnosis but reduces sensi-
tivity.
Two sexually transmitted infections (Chlamydia trachomatis and
Neisseria gonorrhoeae) have been strongly implicated in the aetiol-
ogy of PID; however, based on the pattern of organisms isolated
from the upper genital tract, the infectionmay often be polymicro-
bial (caused bymore than one type of bacteria) (Eschenbach 1975;
Arredondo 1997; Baveja 2001;Haggerty 2006). This suggests that
initial damage produced by C trachomatis or N gonorrhoeae may
permit the opportunistic entry of other bacteria, including anaer-
obes (bacteria that do not need oxygen to grow) (Ross 2014b).
The public health importance of PID can be estimated from
the frequency of chlamydial and gonococcal infections. In 2012,
among women aged 15 to 49 years, the estimated global preva-
lence of chlamydia was 4.2% (95% confidence interval (CI) 3.7%
to 4.7%), gonorrhoea (0.8%, 95% CI 0.6% to 1.0%), and tri-
chomoniasis (5.0%, 95% CI 4.0% to 6.4%) (Newman 2015). In
a prospective study of 1170 women with elevated risk for hav-
ing chlamydial cervicitis, 8.6% developed PID within three years;
among women with chlamydia, the risk ratio (RR) for developing
PID was 2.5 (95% CI 1.5 to 4.0) (Ness 2006). In the UK, the
prevalence of PID is around 2% among women between 16 and
46 years old (Simms 1999; Datta 2012; Ross 2014b). However, in
some other countries, the rates of chlamydia infection are lower, for
example, in Jordan it is 0.6 and 0.5% in symptomatic and asymp-
tomatic women, respectively (Mahafzah 2008). Among women
with PID, 10% to 20% may become infertile, 40% will develop
chronic pelvic pain, and 10% of those who conceive will have
an ectopic pregnancy (Blanchard 1998; Ness 2002; Ness 2005;
Mahafzah 2008).
The morbidity associated with PID relates to the acute inflamma-
tory process, which can cause abdominal pain, vaginal discharge,
dyspareunia (pain during sexual intercourse), and abnormal men-
strual bleeding. In addition, long-term complications secondary to
tubal damage occur and include chronic pelvic pain, ectopic preg-
nancy, and infertility (Workowski 2015). PID has a prevalence of
between 2% and 12%, and it cannot be diagnosed reliably from
clinical symptoms and signs, which have a positive predictive value
for salpingitis of only 65% to 90% compared with laparoscopy
(Workowski 2015). Direct visualization of the fallopian tubes via
laparoscopy has a higher sensitivity, but there is considerable inter-
and intra-observer reproducibility (Molander 2003). Endometrial
biopsy may have some utility (Ross 2004), but is not performed
routinely and is of uncertain diagnostic and prognostic value, since
endometritis (infection of the inner mucosal lining of the uterus)
can persist despite the resolution of clinical symptoms (Ness 2002;
Savaris 2007).
The financial cost of pelvic infection has been estimated to exceed
USD 2.4 billion in the USA, and the mean total cost per episode
is around USD 5000 (Trent 2011). In the UK, the mean cost of
a non-complicated episode of PID is GBP 163 (Aghaizu 2011).
Description of the intervention
The main intervention for acute PID is the use of broad-spectrum
antibiotics which cover C trachomatis, N gonorrhoeae, and anaero-
bic bacteria. There are three routes of administration (intravenous,
intramuscular, or oral). These routes of administration (oral and
intramuscular versus intravenous) have been considered effective
(Ness 2002; Walker 2007). In refractory cases, surgery to drain an
abscess or hydrosalpinx may be necessary. When parenteral treat-
ment is used, it is usually discontinued 24 hours after a woman
improves clinically (Workowski 2015).
The optimal treatment strategy is unclear. A variety of antibiotic
regimens have been used, with marked geographical variation.
Current practice generally involves the use of multiple agents to
cover C trachomatis,N gonorrhoeae, and anaerobic bacteria, but the
best combination of agents is unknown. The background preva-
lence and antimicrobial resistance patterns of bacterial pathogens
in different regions may influence the choice of empirical therapy.
6Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Guidelines have been produced in the USA (Workowski 2015),
and in Europe (Judlin 2010b; Ross 2014a), to guide therapy, but
these have not been based on a formal systematic review. In ad-
dition, to choose an antibiotic for PID treatment, it is necessary
to consider its spectrum, cost, adverse effects, and posology (i.e.
dosage, interval) to achieve the best balance between compliance
and efficacy. There are no current systematic reviews on this topic.
The different antibiotic regimens proposed to treat PID vary in
cost, reported efficacy, and adverse effects. Potential adverse effects
of therapy for PID include allergic reactions and gastrointestinal
symptoms, which can lead to discontinuation of therapy. Lack of
evidence is revealed in the currentCDCandBritishAssociation for
Sexual Health and HIV (BASHH) guidelines, where the authors
state that there is limited evidence for the need to eradicate anaer-
obes and for the use of alternative regimens, such as azithromy-
cin (Workowski 2015), and the comparison between clindamycin
plus aminoglycoside and fluoroquinolones (Ross 2014a). Like-
wise, if the prevalence of N gonorrhoeae is low, the use of fluoro-
quinolones can be considered if allergy to cephalosporin is an issue
(Workowski 2015).
How the intervention might work
It is likely that the intervention works by eradicating bacterial
pathogens and reducing the associated inflammation which leads
to scarring. Necrotic tissue and pus present in an abscess may pre-
vent antibiotics reaching the infected area. Mechanical drainage
of the abscess through open surgery, laparoscopy, or aspiration
through a large bore needle is likely to work by removing infected
material which antibiotics are unable to treat (Workowski 2015).
Clinical cure without surgery in women with a tubo-ovarian ab-
scess is around75%(DeWitt 2010). The rationale for using broad-
spectrumantibiotics is to cover thewide variety of pathogens found
in PID, which include Gram-positive (e.g. Streptococcus), Gram-
negative (e.g.Chlamydia,Klebsiella,Escherichia coli,Neisseria), and
anaerobic bacteria (Gram positive or negative: Peptostreptococcus,
Bacteroides).
Why it is important to do this review
PID is a common disease (4.4%) that is accompanied by high
rates of morbidity in young women (Ness 2002; Morris 2014).
It requires effective treatment to reduce the incidence of chronic
pelvic pain, infertility, and transmitted STDs. A variety of differ-
ent antibiotic regimens have been proposed to treat PID, which
vary in cost, reported efficacy, and adverse effects, but the optimal
treatment strategy is unclear.
Currently there are no systematic reviews of this subject and the
optimal treatment strategy is unclear. This review will address clin-
ical questions raised by current guidelines on the treatment of
PID (Ross 2014a; Workowski 2015), regarding the effectiveness
and safety of nitroimidazole, the relative benefits of azithromycin
versus doxycycline, the use of quinolones, and the relative bene-
fits of cephalosporins compared to the most-used regimen of clin-
damycin plus aminoglycoside, to inform future guideline devel-
opment and clinical practice.
O B J E C T I V E S
To assess the effectiveness and safety of antibiotic regimens used
to treat pelvic inflammatory disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), including those which did
not describe theirmethod of randomization (i.e. where the authors
stated that treatment was randomized without providing further
details). We chose randomized trials as providing the strongest
evidence for evaluating the efficacy of therapy (Higgins 2011).We
included studies irrespective of publication status or language.
We excluded quasi-randomized trials because they produce effects
estimates indicating more extreme benefits when compared with
RCTs (Higgins 2011). We also excluded cross-over and cluster
trials.
Types of participants
Women of reproductive age (14 years of age or older) diagnosed
as having acute PID (symptoms for less than six weeks) based on
clinical findings, laparoscopy, endometrial biopsy, or detectable
gonorrhoea or chlamydia in the upper genital tract.
We divided women into two groups: mild-moderate (e.g. absence
of tubo-ovarian abscess) and severe (e.g. systemically unwell, pres-
ence of tubo-ovarian abscess).
Types of interventions
We limited our review to comparison of drugs in current use that
are recommended for consideration by the 2015 US CDC guide-
lines for treatment of PID (Workowski 2015).
We included trials comparing the following treatments for PID:
• azithromycin versus doxycycline;
• quinolone versus cephalosporin;
• nitroimidazole versus no nitroimidazole;
• clindamycin plus aminoglycoside versus quinolone;
• clindamycin plus aminoglycoside versus cephalosporin.
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Types of outcome measures
Primary outcomes
• Effectiveness: clinical cure according to the criteria defined
by the treating physician (e.g. resolution or improvement of signs
and symptoms related to PID).
• Adverse events: any antibiotic-related adverse event leading
to discontinuation of therapy.
Secondary outcomes
• Microbiological clearance of chlamydia from either the
upper or lower genital tract, according to the method provided
by the authors.
• Microbiological clearance of gonorrhoea from either the
upper or lower genital tract, according to the method provided
by the authors.
• Laparoscopic evidence of resolution of PID based on
physician opinion.
• Length of stay (for inpatient care).
• Rate of fertility based on at least one participant-reported
live birth following PID treatment in women not using effective
contraception.
Where studies included women with various types of pelvic in-
fection, we considered only women with endometritis, salpingitis,
parametritis, or oophoritis (not related to labour, delivery, cancer,
or surgery).
Where studies reported multiple time points, we considered the
period between 14 and 28 days after initiation of treatment.
Search methods for identification of studies
We identified relevant RCTs of ’antibiotic therapy’ for ’PID’,
irrespective of their language of publication, publication date,
and publication status (published, unpublished, in press, and
in progress). We used both electronic searching in bibliographic
databases and handsearching, as described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Electronic searches
We contacted the Information Specialist of the Cochrane Sexually
Transmitted Infections ReviewGroup to implement a comprehen-
sive search strategy capturing as many relevant RCTs as possible in
electronic databases. We used a combination of controlled vocab-
ulary (MeSH, Emtree, DeCS, including exploded terms) and free-
text terms (considering spelling variants, synonyms, acronyms, and
truncation) for ’pelvic inflammatory disease (PID)’ and ’antibi-
otic therapy’, with field labels, proximity operators, and Boolean
operators. We have presented the search strategies in Appendix 1.
Specifically, we searched the following electronic databases.
• The Cochrane Sexually Transmitted Infections Review
Group’s Specialized Register, which includes RCTs from 1944 to
2016 located through electronic searching and handsearching.
The electronic databases searched for the register are
CENTRAL, MEDLINE, and Embase.
• The Cochrane Central Register of Controlled Trials
(CENTRAL), Ovid platform (1991 to 11 July 2016).
• MEDLINE, Ovid platform (1946 to 11 July 2016).
• MEDLINE In-Process & Other Non-Indexed Citations,
Ovid platform (1946 to 11 July 2016).
• MEDLINE Daily Update, Ovid platform (1946 to 11 July
2016).
• Embase (1947 to 11 July 2016).
• LILACS, iAHx interface (1982 to 11 July 2016).
• Web of Science (2001 to July 2016).
In MEDLINE, we used the Cochrane Highly Sensitive Search
Strategy for identifying RCTs: sensitivity and precision maximiz-
ing version (2008 revision), Ovid format (Higgins 2011). The
LILACS search strategy combined RCTs filter of iAHx interface.
Searches were updated to within 12 months of publication of the
review.
Searching other resources
We attempted to identify other relevant RCTs using the methods
below.
We searched the following trials registers:
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/);
• ClinicalTrials.gov (ClinicalTrials.gov/).
We searched for grey literature in OpenGrey (www.opengrey.eu/)
(1990, 1992, 1995, 1996, and 1997). We contacted authors of
all RCTs identified by other methods as well as pharmaceutical
companies producing ’antibiotic therapy’ for ’pelvic inflammatory
disease (PID).’
We handsearched conference proceeding abstracts in the following
publications: Indian Journal of Sexually Transmitted Diseases (2007
to July 2016), Sexually Transmitted Diseases (1974 to July 2016),
Sexually Transmitted Infections (1996 to July 2016), Journal of Sex-
ual Medicine (2004 to July 2016), Sexual and Relationship Therapy
(2000 to July 2016), and the Society for the Scientific Study of
Sexuality’s Sexual Science Newsletter (2000 to July 2016).
We handsearched previous systematic reviews on similar topics
identified from:
• the Cochrane Library (www.thecochranelibrary.com/);
• Epistemonikos (www.epistemonikos.org/).
We handsearched the reference lists of all identified RCTs.
Data collection and analysis
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Selection of studies
Two review authors (DGF and RVD) performed an initial screen
of titles and abstracts retrieved by the search, and we retrieved
the full text of all potentially eligible studies. Two review authors
(DGF and RVD) independently examined these studies for com-
pliance with the inclusion criteria and selected studies that met
these criteria. We resolved disagreements regarding eligibility by
discussion or by consulting a third review author (JR). We docu-
mented the selection process in a PRISMA flow chart (Figure 1).
We excluded pelvic infection related to obstetric or surgical pro-
cedures. Where a study contained both ’eligible’ and ’ineligible’
participants, we included a subset of data relating to the ’eligible’
participants if sufficient details were provided for analysis.
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Figure 1. Study flow diagram.
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Data extraction and management
Three review authors (SF, DGF, RVD) independently extracted
data from each study using a data extraction form that the review
authors designed and pilot tested. We collected data from the in-
cluded studies in sufficient detail to complete the Characteristics
of included studies table. We also extracted detailed numerical
outcome data in duplicate to allow calculation of Mantel-Haen-
szel RRs for each comparison. We examined data for errata, re-
traction, fraud, and inconsistencies. We resolved disagreements by
consensus or by consulting a fourth review author (JR or RFS).
If a study had more than two intervention arms, we included or
combined only those that met the predefined inclusion criteria.
For instance, if the study compared azithromycin (group A) versus
azithromycin plus metronidazole (group B) versus metronidazole
plus cefoxitin or doxycycline (group C), and the analysis was be-
tween the use or not of metronidazole, we combined groups B and
C versus group A. The treatment effect was expressed as rate of
cure (%) and its magnitude and direction checked in forest plots
to ensure consistency with the original study. Where studies had
multiple publications, we used the main trial report as the ref-
erence and derived additional details from secondary papers. We
corresponded with study investigators for further data as required.
Data collected with the data extraction form were piloted-tested
and included:
• Study factors:
◦ author, date of publication, journal;
◦ date of study;
◦ study design;
◦ location;
◦ setting;
◦ quality of randomization, treatment allocation, and
blinding;
◦ method of PID diagnosis;
◦ sample size.
• Participant factors:
◦ age, ethnicity;
◦ pregnancy;
◦ presence of intrauterine device (IUD);
◦ duration of symptoms;
◦ presence of abscess (pyosalpinx, tubo-ovarian abscess).
• Outcome measured:
◦ method of assessment of pelvic pain and score;
◦ timing of assessment;
◦ adverse events;
◦ additional assessments of outcome: laparoscopy,
microbiology, fertility.
• Intervention factors:
◦ antibiotic given: dose, route, length of therapy;
◦ comparator regimen: dose, route, length of therapy;
◦ additional treatment given.
• Additional data:
◦ whether contact tracing was performed.
Assessment of risk of bias in included studies
Three review authors (SF, DGF, RVD) independently assessed the
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements between two review authors by con-
sensus or by involving a third review author (JR or RFS). We as-
sessed risk of bias using the Cochrane ’Risk of bias’ tool provided
in Review Manager 5 (RevMan 2014). We provided justification
for risk of bias (high, low, unclear) in the ’Risk of bias’ table by
direct reference to the relevant report. We requested missing infor-
mation from the study investigators using open-ended questions.
1. Random sequence generation (checking for possible
selection bias)
For each included study, we verified the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• unclear risk of bias (e.g. authors stated that women were
randomized to one of the treatments, without further
explanation).
2. Allocation concealment (checking for possible selection
bias)
For each included study, we verified the method used to conceal
allocation to interventions prior to assignment, and we assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered, sealed, opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth); or
• unclear risk of bias (allocation was mentioned without
further details).
3.1. Blinding of participants and personnel (checking for
possible performance bias)
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For each included study, we verified the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be
at:
• low risk of bias if participants and personnel were blinded,
or if we judged that the lack of blinding would be unlikely to
affect results (e.g. culture for N gonorrhoeae);
• high risk if participants and personnel were not blinded;
• unclear risk of bias if no further details were provided.
3.2. Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we verified the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes. We assessed methods used to
blind outcome assessment as:
• low risk of bias if assessors were blinded, or if we judged
that the lack of blinding would be unlikely to affect results (e.g.
culture for N gonorrhoeae);
• high risk if assessors were not blinded;
• unclear risk of bias if no further details were provided.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we verified the completeness of data, including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomized participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we re-included missing data in the
analyses we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization); or
• unclear risk of bias: no further details were provided.
We used a cutoff point of 20% missing data in determining if a
study was at low or high risk of bias (Fewtrell 2008).
5. Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all the study’s
prespecified outcomes and all expected outcomes of interest to
the review were reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study did not
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias: no further details were provided.
6. Other bias (checking for bias due to problems not covered
by 1. to 5. above)
For each included study, we described any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of bias;
• high risk of bias; or
• unclear whether there is risk of bias.
7. Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to criteria described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to 1. to 6. above, we assessed the likely magnitude and
direction of the bias and whether we considered that it was likely
to impact on the findings. We explored the impact of the level of
bias by undertaking sensitivity analyses (see Sensitivity analysis).
Measures of treatment effect
For dichotomous data, we used number of events in the con-
trol and intervention groups to calculate Mantel-Haenszel risk
ratios (RR). We presented 95% confidence intervals (CI) for all
outcomes. For number need to treat for an additional beneficial
(NNTB) or harmful (NNTH) outcome, we followed the recom-
mendation given by Altman (Altman 1998). When we observed
a treatment effect we reported the NNTH or NNTB were given
with their 95% CIs.
When possible, we performed analysis based on intention to treat
(ITT). When information for an ITT analysis was not available,
we used the results provided by the authors.
We performed meta-analysis separately for mild-moderate PID
and severe PID. We defined severe PID as the presence of tubo-
ovarian abscess, being systemically unwell, or the presence of peri-
tonitis, and mild-moderate PID as no presence of tubo-ovarian
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abscess. We further analyzed cases in these two groups across dif-
ferent classes of antibiotics.
Unit of analysis issues
The primary unit of analysis was an event per woman random-
ized, which was used to calculate the percentage response rate (e.g.
clinical cure).
Dealing with missing data
We analyzed the data on an ITT basis to the greatest degree pos-
sible and made attempts to obtain missing data from the original
trials. Where we were unable to obtain these data, we considered
cases that were lost to follow-up as treatment failure (worst-case
scenario) in the primary analysis. For other outcomes, we analyzed
the available data. We did not analyze data from other reported
outcomes (e.g. pooled rates of cure of different diseases, including
PID).
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity by measure of the I2 statistic as follows:
low (l2 value below 40%), moderate (l2 value of 40% to 75%), or
high (l2 value above 75%) (Sutton 2008; Higgins 2011). We also
assessed statistical heterogeneity in each meta-analysis using the t
2 and Chi2 statistics.
We regarded heterogeneity as substantial if I2 was greater than
40% and either t2 was greater than zero, or there was a low P value
(less than 0.10) in the Chi2 test for heterogeneity. If we detected
substantial heterogeneity, we explored possible explanations for
it in subgroup analyses (see Subgroup analysis and investigation
of heterogeneity). We took statistical heterogeneity into account
when interpreting the results, especially if there was any variation
in the direction of effect. If so, we used random-effects analysis,
instead of fixed-effect analysis.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. Some types
of reporting bias (e.g. publication bias, multiple publication bias,
language bias, etc.) reduce the likelihood that all studies eligible for
a review are retrieved (Higgins 2011). If all eligible studies are not
retrieved, the review would be biased. In view of the difficulty of
detecting and correcting for publication bias and other reporting
biases, we aimed to minimize their potential impact by ensuring
a comprehensive search for eligible studies and by being alert for
duplication of data. If there were 10 or more studies in an analysis,
we used a funnel plot to explore the possibility of small-study
effects (a tendency for estimates of the intervention effect to be
more beneficial in smaller studies).
Data synthesis
We performed statistical analyses using Review Manager 5 (
RevMan 2014). We used a fixed-effect meta-analysis for combin-
ing data where it was reasonable to assume that trials were esti-
mating the same underlying treatment effect (i.e. where trials were
examining the same intervention, and the trials’ populations and
methods were sufficiently similar). We conducted separate analy-
ses for mild-moderate and severe PID.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if we detected
substantial statistical heterogeneity (I2 40% or greater), we used a
random-effects meta-analysis to produce an overall summary if a
mean treatment effect across trials was considered clinically mean-
ingful. We treated the random-effects summary as the mean range
of possible treatment effects, and discussed the clinical implica-
tions of treatment effects differing between trials.
If the mean treatment effect was not clinically meaningful, we did
not combine trials. Where we used random-effects analyses, we
presented the results as the mean treatment effect with 95% CIs,
and the estimates of the t2 and I2 statistics.
Subgroup analysis and investigation of heterogeneity
Where data were available, we performed the following prespeci-
fied subgroup analyses:
• route of antibiotic administration (oral, intramuscular, or
intravenous);
• length of therapy (less or more than seven continuous days
receiving antibiotics);
• detection of chlamydia;
• detection of gonorrhoea;
• site of initiation of treatment (inpatient or outpatient).
We avoided selective reporting of a particular subgroup by not
performing multiple subgroup analysis. If we identified substan-
tial heterogeneity (I2 40% or greater), we used a random-effects
analysis as the primary statistical analysis.
Where there was substantial heterogeneity, we explored possible
reasons for this finding by stratifying results according to the char-
acteristics of the study population (e.g. method of PID diagnosis),
the intervention (e.g. class of antibiotics used, dose of antibiotic,
route of administration), or methodological characteristics (e.g.
length of time to outcome measurement).
Sensitivity analysis
We undertook the following sensitivity analysis to investigate
whether our conclusions were robust to methodological decisions
made by review authors:
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• risk of bias (restricting analysis to blinded studies at low risk
of selection bias).
Grading the quality of evidence
We used GRADEpro software (GRADEpro GDT 2014) to pro-
duce ’Summary of findings’ tables. TheGRADE approach consid-
ers the following criteria: risk of bias, inconsistency, indirectness
of evidence, imprecision, and publication bias, and specifies four
levels of quality: high, moderate, low, and very low, starting from
high for RCTs. If there was a flaw in the RCT, we downgraded the
quality of the evidence by one or two levels.
Two review authors independently applied a consistent grading
for GRADE in the ’Summary of findings’ tables. We resolved any
disagreements by consensus. We downgraded for risk of bias due
to crucial risk of bias for two or more criteria (as it was graded
in Figure 2). The evidence was downgraded further if there was
inconsistency. Inconsistency was based on statistical test for het-
erogeneity and how much variation there was in the findings of
the studies that contributed to the outcome. We also considered
imprecision, and downgraded if the CIs were compatible with
benefit in one or both groups, or with no difference between the
groups. In each domain, we downgraded one level for serious risk
of bias and two levels for very serious risk of bias.
14Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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R E S U L T S
Description of studies
Results of the search
We retrieved 2133 references and screened 2094 records after re-
movingduplicated references.Wediscarded1955 records as clearly
irrelevant and considered 139 full-text articles. After full-text re-
view, 37 studies met our inclusion criteria and we excluded 102
studies (Figure 1). The reasons for exclusion of the 102 full-text
studies are explained in the Characteristics of excluded studies ta-
ble. We extracted data from the full-text article for each study.
Included studies
The 37 included trials had 6348 women, with a sample size rang-
ing from 25 (Apuzzio 1989), to 1156 (Aicio lu 2013). Retrieved
studies came from awide range of inpatient and outpatient settings
from different continents (Americas, Europe, Asia, Oceania, and
Africa) and were written in English, German, French, Japanese,
and Italian.
Population
The included trials recruited women aged 14 years and over with
diagnosis of PID according to CDC criteria (pelvic or lower ab-
dominal pain and one or more of the following clinical criteria:
cervical motion tenderness, uterine tenderness, or adnexal ten-
derness) (Workowski 2015). Studies varied in degree of disease
severity of participants, treatment location (i.e. inpatient or outpa-
tient), and countries and continents. PID was considered severe in
the presence of systemically unwell women, peritonitis, or pelvic
abscess.
Interventions
The 37 RCTs yielded 6348 women and made the following com-
parisons.
For mild-moderate PID:
• azithromycin versus doxycycline (Malhotra 2003; Savaris
2007);
• cephalosporin versus quinolone (Wendel 1991; Martens
1993; Arredondo 1997);
• nitroimidazole versus no nitroimidazole (Burchell 1987;
Tison 1988; Hoyme 1993; Ross 2006; Judlin 2010a; Aicio lu
2013);
• clindamycin plus aminoglycoside versus quinolone
(Apuzzio 1989);
• clindamycin plus aminoglycoside versus cephalosporin
(Walters 1990).
For severe PID:
• azithromycin versus doxycycline (Bevan 2003);
• quinolone versus cephalosporin (Okada 1988; Martens
1993; Fischbach 1994);
• nitroimidazole versus no nitroimidazole (Ciraru-Vigneron
1986; Crombleholme 1986; Crombleholme 1987; Leboeuf
1987; Buisson 1989; Ciraru-Vigneron 1989; Giraud 1989;
Heinonen 1989; Fischbach 1994; Sirayapiwat 2002; Heystek
2009);
• clindamycin plus aminoglycoside versus quinolone
(Crombleholme 1989; Thadepalli 1991);
• clindamycin plus aminoglycoside versus cephalosporin (Roy
1985; Sweet 1985; Soper 1988; Martens 1990; Roy 1990;
Walters 1990; Landers 1991; Maria 1992; Hemsell 1994; Balbi
1996).
Outcomes
The main outcome was clinical cure, and 5147 women were re-
ported as clinically cured.We defined clinical cure according to the
authors’ definitions, which ranged from absence of symptoms for
24 hours (Apuzzio 1989), to a 60% or greater reduction in total
pain score at day 21 combined with an absence of pelvic discom-
fort/tenderness, temperature less than 37.8 °C, and white blood
cell level less than 10,000/mm3 on day 21 (Aicio lu 2013). Most
of the trials used clinical parameters for cure, that is, defervesce,
reduction, or absence of pain at different time points after treat-
ment. We identified adverse effects leading to discontinuation of
treatment as those related to suspension of therapeutic regimen.
Excluded studies
We excluded 102 studies. The most common reason for exclusion
was that the study did not report a comparison of interest to this
review (47 studies). Other common reasons for exclusion were
that PID cases were not distinguished from other pelvic infectious
conditions (21 studies) or the studies was not randomized (14
studies) (see Characteristics of excluded studies table).
Risk of bias in included studies
We performed a full risk of bias assessment on all included studies.
We classified those studies where authors stated that women were
randomized to one of two treatments, without further details,
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as at unclear risk of selection bias. Many of these studies were
performed before the year 2000, and predated the introduction of
CONSORT guideline.
We have summarized the risk of bias in Figure 2 and Figure
3. Additional details of the included trials are provided in the
Characteristics of included studies table.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Twelve trials adequately reported a truly random process of se-
quence generation, for example, random number table or com-
puter random number generator, making selection bias at entry
unlikely (Sweet 1985; Soper 1988; Martens 1990; Walters 1990;
Thadepalli 1991; Martens 1993; Sirayapiwat 2002; Malhotra
2003; Ross 2006; Savaris 2007; Judlin 2010a; Aicio lu 2013).
The remaining included trials did not report the random sequence
generation methods, making the risk of selection bias at entry un-
clear.
For allocation concealment, four trials implemented sequentially
numbered drug containers as a concealment allocation method,
making selection bias at entry unlikely (Ross 2006; Savaris 2007;
Judlin 2010a; Aicio lu 2013). The remaining included trials did
not report the method used to conceal allocation to interventions
prior to assignment, making the risk of selection bias at entry
unclear.
Blinding
Six trials used placebo with identical appearance for the con-
trol group to blind trial participants and personnel, making
performance and detection bias unlikely (Figure 2) (Okada
1988; Arredondo 1997; Ross 2006; Savaris 2007; Heystek 2009;
Judlin 2010a). In 10 studies, investigators and participants were
not blinded to the allocation, making them at high risk of
bias (Crombleholme 1986; Crombleholme 1989; Walters 1990;
Landers 1991; Wendel 1991; Maria 1992; Hemsell 1994; Bevan
2003; Malhotra 2003; Aicio lu 2013). The remaining included
trials did not specify how the participants and the personnel were
blinded from knowledge of which intervention a participant re-
ceived, making the risk of performance and detection bias unclear.
Incomplete outcome data
Completeness of data was adequate (i.e. less than 20% of data
missing) for 28 of the studies (Figure 2) (Roy 1985; Sweet 1985;
Crombleholme 1987; Leboeuf 1987; Okada 1988; Soper 1988;
Apuzzio 1989; Ciraru-Vigneron 1989; Crombleholme 1989;
Giraud 1989; Heinonen 1989; Martens 1990; Roy 1990; Walters
1990; Landers 1991; Thadepalli 1991; Hoyme 1993; Martens
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1993; Fischbach 1994; Hemsell 1994; Balbi 1996; Sirayapiwat
2002; Bevan 2003; Malhotra 2003; Ross 2006; Savaris 2007;
Heystek 2009; Judlin 2010a).
The remaining studies had more than 20% of data missing, with
an associated high risk of attrition bias.
Selective reporting
For most of the included studies, the trial protocol was not avail-
able, and it was unclear whether the published reports included
all the expected outcomes, including those that were prespecified.
The reports had insufficient information to permit judgement of
’yes’ or ’no’, and were therefore rated as at unclear risk of bias. For
three trials, the trial protocol was available, and it was clear that the
published reports included all the expected outcomes, including
those that were prespecified, making reporting bias unlikely (Ross
2006; Savaris 2007; Aicio lu 2013).
Other potential sources of bias
One study had imbalances in baseline characteristics and was at
high risk of potential bias (Soper 1988). Out of 37 trials, 13 had
some form of funding by pharmaceutical companies (Arredondo
1997;Crombleholme 1989; Hemsell 1994; Heystek 2009; Judlin
2010a; Landers 1991; Martens 1993; Ross 2006; ;Roy 1990;
Savaris 2007; Thadepalli 1991; Walters 1990; Wendel 1991);
however, there is no clear evidence that trial methods are more
likely to be flawed if a trial is industry funded (Sterne 2013), there-
fore these trials were rated as at unclear risk. The remaining trials
provided insufficient information to permit a judgement of ’yes’
or ’no’ and were therefore rated as at unclear risk of bias.
Assessment of reporting bias
We explored publication bias through visual assessment of funnel
plot asymmetry when there were data from 10 or more trials in the
same analysis.We constructed a funnel plot forAnalysis 3.3 (Figure
4) and noted some asymmetry in the plot, suggestive of potential
publication bias. There are five possible causes for the asymmetric
funnel plot: reporting bias, poor methodological quality, true het-
erogeneity, artefactual, and chance (Egger 1997). Only through
formal statistical analysis or using ’contour-enhanced’ funnel plot
is an explication for these asymmetrical funnel plots possible. Al-
though it is usually impossible to know the precise mechanism for
funnel plot asymmetry, publication bias could explain the pres-
ence of an asymmetrical funnel plot.
Figure 4. Funnel plot of comparison: 3.2 Effectiveness of cure in severe PID in regimens containing
nitroimidazoles versus without nitroimidazoles.
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Effects of interventions
See: Summary of findings for the main comparisonMacrolides
(azithromycin) compared to tetracycline (doxycycline) for pelvic
inflammatory disease (PID); Summary of findings 2 Quinolone
compared to cephalosporins for pelvic inflammatory disease;
Summary of findings 3 Nitroimidazole compared to no
nitroimidazole for pelvic inflammatory disease; Summary of
findings 4 Clindamycin plus aminoglycoside compared to
quinolone for pelvic inflammatory disease; Summary of findings
5 Clindamycin plus aminoglycoside compared to cephalosporin
for pelvic inflammatory disease
We analyzed effectiveness of clinical cure and adverse effects lead-
ing to discontinuation of treatment in five scenarios based on drug
class comparison:
• regimens containing macrolides (azithromycin) versus
tetracycline (doxycycline);
• regimens containing quinolones versus cephalosporin;
• regimens containing nitroimidazoles versus without
nitroimidazoles;
• regimens containing clindamycin plus aminoglycoside
versus quinolone;
• regimens containing clindamycin plus aminoglycoside
versus cephalosporin.
We analyzed the efficacy of therapy in these five comparisons in
women with mild-moderate PID and women with severe PID.
We also compared adverse events leading to discontinuation of
the therapy. Lack of further analysis is discussed in the Differences
between protocol and review section.
1. Regimens containing macrolides (azithromycin)
versus tetracycline (doxycycline)
Three studies compared azithromycin versus doxycycline in mild-
moderate (Malhotra 2003; Savaris 2007) or severe (Bevan 2003)
PID.
Primary outcomes
1.1. Effectiveness
1.1a. Clinical cure in mild-moderate pelvic inflammatory
disease
We included two trials in the analysis of clinical cure in mild-
moderate PID (Malhotra 2003; Savaris 2007). There was no clear
evidence of a difference between azithromycin and doxycycline
regimens (RR 1.18, 95% CI 0.89 to 1.55; 243 women; 2 studies;
I2 = 72%; very low-quality evidence) (Analysis 1.1; Figure 5).
Figure 5. 1.1 Effectiveness of cure in mild-moderate PID on regimens containing macrolides (azithromycin)
versus tetracycline (doxycycline) using ITT.
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In a sensitivity analysis limited to the study at low risk of bias,
azithromycin was superior to doxycycline in achieving cure in
mild-moderate PID (RR 1.35, 95% CI 1.10 to 1.67, 133 women,
moderate-quality evidence) (Analysis 1.2)
1.1b. Clinical cure in severe pelvic inflammatory disease
One trial reported clinical cure in severe PID (Bevan 2003). There
was no clear evidence of a difference in rates of cure between
regimens using azithromycin or doxycycline to treat severe PID
(RR 1.00, 95% CI 0.96 to 1.05; 309 women; 1 study; low-quality
evidence) (Analysis 1.3; Figure 6.
Figure 6. 1.2 Effectiveness of cure in severe PID in regimens containing macrolides (azithromycin) versus
tetracycline (doxycycline).
1.2. Adverse events
1.2.1. Antibiotic-related adverse effects leading to
discontinuation of therapy
We included three trials in the analysis of antibiotic-related ad-
verse effects leading to discontinuation of therapy (Bevan 2003;
Malhotra 2003; Savaris 2007). There was no clear evidence of a
difference between the groups (RR 0.71, 95% CI 0.38 to 1.34;
552 women; 3 studies; I2 = 0%, low-quality evidence) (Analysis
1.4).
Data are depicted in Summary of findings for the main
comparison.
Secondary outcomes
1.3. Microbiological clearance of chlamydia
Two studies reported chlamydia clearance (Bevan 2003; Savaris
2007) and cure was obtained in 49/50 women in the azithromycin
group (cure 98%, 95% CI 89% to 100%) and 33/33 women in
the doxycycline group (cure 100%, 95% CI 90% to 100%).
1.4. Microbiological clearance of gonorrhoea
Two studies reported gonorrhoea clearance (Bevan 2003; Savaris
2007), but only one found evidence of N gonorrhoeae (Bevan
2003). In the azithromycin group, there was cure in 11/11 cases
(100%, 95% CI 74% to 100%). Cure was also 100% in the doxy-
cycline group (5/5 cases; 100%, 95% CI 57% to 100%).
1.5. Laparoscopic evidence of resolution of pelvic
inflammatory disease based on physician opinion
We found no data for laparoscopic evidence of resolution of PID.
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1.6. Length of stay (for inpatient care)
One study reported length of hospital stay (Bevan 2003). Women
were kept in the hospital, per protocol, for 13 to 18 days.
1.7. Rate of fertility
We found no data for rate of fertility.
2. Regimens containing quinolones versus
cephalosporins
Six studies compared quinolones versus cephalosporins in mild-
moderate PID (Wendel 1991; Martens 1993; Arredondo 1997)
or severe PID (Okada 1988; Martens 1993; Fischbach 1994).
Primary outcomes
2.1. Effectiveness
2.1a. Clinical cure in mild-moderate pelvic inflammatory
disease
We included three trials in the analysis of clinical cure in mild-
moderate PID (Wendel 1991; Martens 1993; Arredondo 1997).
There was no clear evidence of a difference between the groups
(RR 1.04, 95% CI 0.98 to 1.10; 459 women; 3 studies; I2 = 5%;
low-quality evidence) (Analysis 2.1).
2.1b. Clinical cure in severe pelvic inflammatory disease
We included two trials in the analysis of clinical cure in severe PID
(Okada 1988; Fischbach 1994). There was no clear evidence of a
difference in rates of cure between regimens using quinolones or
cephalosporins to treat severe PID (RR1.06, 95%CI 0.91 to 1.23;
313 women; 2 studies; I2 = 7%; low-quality evidence) (Analysis
2.2).
2.2. Adverse events
2.2.1. Antibiotic-related adverse effect leading to
discontinuation of therapy
The five trials reported few adverse effects leading to discontinu-
ation of treatment (quinolones: 1.2%, 95% CI 0.5 to 2.9 versus
cephalosporin: 0.5%, 95% CI 0.1 to 1.9%), with no clear evi-
dence of a difference in rates of discontinuation (RR 2.24, 95%
CI 0.52 to 9.72; 772 women; 5 studies; I2 = 0%, very low-quality
evidence) (Okada 1988; Wendel 1991; Martens 1993; Fischbach
1994; Arredondo 1997) (Analysis 2.3).
Data are depicted in Summary of findings 2.
Secondary outcomes
2.3. Microbiological clearance of chlamydia
Five studies reported chlamydia clearance (Martens 1990;Wendel
1991; Martens 1993; Fischbach 1994; Arredondo 1997), and
three of which reported clearance of chlamydia (Wendel 1991;
Fischbach 1994; Arredondo 1997). Cure occurred in 20/21
women in the quinolone group (95.2%, 95% CI 77% to 99%)
and 25/25 women in the cephalosporin group (100%, 95% CI
86 to 100%).
2.4. Microbiological clearance of gonorrhoea
Five studies reported gonorrhoea clearance (Martens 1990;
Wendel 1991; Martens 1993; Fischbach 1994; Arredondo 1997),
and three of which reported clearance of chlamydia (Wendel
1991; Fischbach 1994; Arredondo 1997). Cure occurred in 27/30
women in the quinolone group (90%, 95% CI 74 to 96%) and
20/21 women in the cephalosporin group (95.2%, 95% CI 77 to
99%).
2.5. Laparoscopic evidence of resolution of pelvic
inflammatory disease based on physician opinion
We found no data for laparoscopic evidence of resolution of PID.
2.6. Length of stay (for inpatient care)
We found no data suitable for analysis for length of hospital stay.
Fischbach and colleagues admitted women for intravenous treat-
ment for two to five days, followed by seven to 12 days of oral
therapy, without further details (Fischbach 1994).
2.7. Rate of fertility
We found no data for rate of fertility.
3. Regimens containing nitroimidazoles versus no
nitroimidazoles
Sixteen studies compared nitroimidazoles versus without ni-
troimidazoles in mild-moderate PID (Burchell 1987; Tison
1988; Ross 2006; Judlin 2010a; Aicio lu 2013) or severe PID
(Ciraru-Vigneron 1986; Crombleholme 1986; Crombleholme
1987; Leboeuf 1987; Buisson 1989; Ciraru-Vigneron 1989;
Giraud 1989;Heinonen 1989; Fischbach 1994; Sirayapiwat 2002;
Heystek 2009).
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Primary outcomes
3.1. Effectiveness
3.1a. Clinical cure in mild-moderate pelvic inflammatory
disease
We included five studies in the analysis of clinical cure in mild-
moderate PID (Burchell 1987; Tison 1988; Ross 2006; Judlin
2010a; Aicio lu 2013). In all the studies the nitroimidazole used
was metronidazole. There was no conclusive evidence of a dif-
ference in effectiveness between metronidazole versus no use of
metronidazole in mild-moderate PID (RR 1.01, 95% CI 0.93 to
1.10; 2427 women; 5 studies; I2 = 60%; moderate-quality evi-
dence) (Analysis 3.1; Figure 7).
Figure 7. 3.1 Effectiveness of cure in mild-moderate PID in regimens containing nitroimidazoles versus
without nitroimidazoles.
Sensitivity analysis restricted to the two studies at low risk of bias
did not substantially change the main findings (RR 1.06, 95%
CI 0.98 to 1.15; 1201 women; 2 studies; I2 = 32%; high-quality
evidence) (Ross 2006; Judlin 2010a) (Analysis 3.2).
3.1b. Clinical cure in severe pelvic inflammatory disease
Eleven studies evaluatednitroimidazole in severe PID; and all stud-
ies used metronidazole (Ciraru-Vigneron 1986; Crombleholme
1986; Crombleholme 1987; Leboeuf 1987; Buisson 1989; Ciraru-
Vigneron 1989; Giraud 1989; Heinonen 1989; Fischbach 1994;
Sirayapiwat 2002; Heystek 2009). There was no evidence of a dif-
ference in clinical cure rates between women treated with metron-
idazole and women not treated with it (RR 0.96, 95% CI 0.92
to 1.01; 1383 women; 11 studies; I2 = 3%; moderate-quality evi-
dence) (Analysis 3.3; Figure 8).
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Figure 8. 3.2 Effectiveness of cure in severe PID in regimens containing nitroimidazoles versus without
nitroimidazoles.
3.2. Adverse events
3.2.1. Antibiotic-related adverse effects leading to
discontinuation of therapy
We analyzed 16 studies pf antibiotic-related adverse effects
leading to discontinuation of therapy (Ciraru-Vigneron 1986;
Crombleholme 1986; Burchell 1987; Crombleholme 1987;
Leboeuf 1987; Tison 1988; Buisson 1989; Ciraru-Vigneron 1989;
Giraud 1989;Heinonen 1989; Fischbach 1994; Sirayapiwat 2002;
Ross 2006; Heystek 2009; Judlin 2010a; Aicio lu 2013). There
was no clear evidence of a difference between groups in rates of
discontinuation of treatment due to adverse effects (RR 1.00, 95%
CI 0.63 to 1.59; 3788 women; 16 studies; I2 = 0%; low-qual-
ity evidence). Of note, out of 16 RCTs, 10 studies did not con-
tribute data to the analysis because the authors reported no adverse
effects (Ciraru-Vigneron 1986; Crombleholme 1986; Burchell
1987; Leboeuf 1987; Tison 1988; Ciraru-Vigneron 1989; Giraud
1989; Heinonen 1989; Sirayapiwat 2002; Heystek 2009). Only
six studies reported adverse effects leading to discontinuation of
treatment, yielding a rate of 1.8% of severe adverse effects (95%
CI 1.2% to 2.5%) in the group not treated with nitroimidazole,
and a rate of 1.7% (95% CI 1.2% to 2.4%) in the group treated
with nitroimidazole.
Sensitivity analysis restricted to the two studies at low risk of bias
did not substantially change the main findings (RR 1.06, 95%
CI 0.98 to 1.15; 1201 women; 2 studies; I2 = 32%; high-quality
evidence) (Ross 2006; Judlin 2010a).
Data are depicted in Summary of findings 3.
Secondary outcomes
3.3. Microbiological clearance of chlamydia
This is not applicable, since nitroimidazoles do not have activity
against chlamydia.
3.4. Microbiological clearance of gonorrhoea
This is not applicable, since nitroimidazoles do not have activity
against gonorrhoea.
3.5. Laparoscopic evidence of resolution of pelvic
inflammatory disease based on physician opinion
We found no data for laparoscopic evidence of resolution of PID.
3.6. Length of stay (for inpatient care)
Burchell and colleagues did not give details of the length of hospital
stay: the authors mentioned that “ampicillin plus metronidazole
in group II began with four 1 g intravenous doses given at 6-hourly
intervals and then 400 mg 8-hourly orally for 14 days” and in
Table III stated “patient response after 4 days treatment” (Burchell
1987).
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Ciraru-Vigneron and colleagues reported that women treated with
amoxicillin plus clavulanate had a stay of 3.6 days and with ampi-
cillin plus gentamicin plus metronidazole had a stay of 3.7 days
(Ciraru-Vigneron 1986).
Buisson and colleagues reported that the mean treatment for the
amoxicillin plus clavulanate group was four days followed by a
mean of 17 days of oral therapy, and for the triple treatment (ampi-
cillin plus gentamicin plus metronidazole) it was seven days per
protocol, due to the use of gentamicin, followed by ampicillin plus
metronidazole until clinical improvement (Buisson 1989).
Ciraru-Vigneron and colleagues reported that the mean duration
of intravenous therapywas 7.6 ± 2.1 days in amoxicillin plus clavu-
lanate and 7.7 ± 2.2 days in the ampicillin plus gentamicin plus
metronidazole group. They did not specify if the oral treatment,
followed intravenous treatment, was performed in hospital, but
both were similar (11.2 ± 4.8 days with amoxicillin plus clavu-
lanate and 11.1 ± 6.6 days with ampicillin plus gentamicin plus
metronidazole) (Ciraru-Vigneron 1989).
Crombleholme and colleagues report that treatment was for 14
days, starting with intravenous infusion and switched to oral,
but they did not provide details if oral therapy was in hospital
(Crombleholme 1989). In their previous study, intravenous treat-
ment length was mentioned as at least five days, without further
details (Crombleholme 1986).
Fischbach and colleagues admitted women for intravenous treat-
ment for two to five days, followed by seven to 12 days of oral
therapy, without further details (Fischbach 1994).
3.7. Rate of fertility
We found no data for rate of fertility.
4. Regimens containing clindamycin plus
aminoglycoside versus quinolone
Three studies compared clindamycin plus aminoglycoside versus
quinolone in mild-moderate PID (Apuzzio 1989) or severe PID
(Crombleholme 1989; Thadepalli 1991).
Primary outcomes
4.1. Effectiveness
4.1a. Clinical cure in mild-moderate pelvic inflammatory
disease
Only one study compared clindamycin with an aminoglycoside
(gentamicin) versus a quinolone (ciprofloxacin) (Apuzzio 1989). It
was unclearwhether therewas any difference between the regimens
(RR 0.88, 95% CI 0.69 to 1.13; 25 women; 1 study; I2 = 0%;
very low-quality evidence) (Analysis 4.1).
4.1b. Clinical cure in severe pelvic inflammatory disease
We included two studies in the analysis of clinical cure in severe
PID (Crombleholme 1989; Thadepalli 1991). There was no clear
evidence of a difference between these regimens in rates of cure
for severe PID (RR 1.02, 95% CI 0.87 to 1.19; 151 women; 2
studies; I2 = 0%; low-quality evidence) (Analysis 4.2).
4.2. Adverse events
4.2.1. Antibiotic-related adverse effects leading to
discontinuation of therapy
The incidence of antibiotic-related adverse effects leading to dis-
continuation of therapy with clindamycin with aminoglycoside
was 0% (95% CI 0% to 4.4%) and with quinolone was 5% (95%
CI 1.9% to 12%). There was no clear evidence of a difference
between regimens (RR 0.21, 95% CI 0.02 to 1.72; 163 women;
3 studies; I2 = 0%; very low-quality evidence) (Analysis 4.3).
Data are depicted in Summary of findings 4.
Secondary outcomes
4.3. Microbiological clearance of chlamydia
Three studies reported chlamydia clearance (Apuzzio 1989;
Crombleholme 1989; Thadepalli 1991), and cure occurred in 10/
10 women in the clindamycin plus aminoglycoside group (100%,
95% CI 72% to 100%) and in 11/12 women in the quinolone
group (92%, 95% CI 65% to 99%).
4.4. Microbiological clearance of gonorrhoea
Three studies reported gonorrhoea clearance (Apuzzio 1989;
Crombleholme 1989; Thadepalli 1991), and cure occurred in 44/
44 women in the clindamycin plus aminoglycoside group (100%,
95% CI 92% to 100%) and in 41/41 women in the quinolone
group (100%, 95% CI 91% to 100%).
4.5. Laparoscopic evidence of resolution of pelvic
inflammatory disease based on physician opinion
We found no data for laparoscopic evidence of resolution of PID.
4.6. Length of stay (for inpatient care)
We found no data suitable for analysis for length of hospital stay.
Crombleholme and colleagues reported that treatment was for
14 days, starting with intravenous infusion and then switched to
oral, but they did not provide details if oral therapy was in hos-
pital (Crombleholme 1989). Appuzio and colleagues did not give
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many details of the length of stay. Theymentioned that women re-
ceived intravenous antibiotics for three to five days until they were
asymptomatic for 24 hours (Apuzzio 1989). Likewise, Thadepalli
reported that women received intravenous ciprofloxacin for three
or more days, followed by oral ciprofloxacin for about one week
(Thadepalli 1991).
4.7. Rate of fertility
We found no data for rate of fertility.
5. Regimens containing clindamycin plus
aminoglycoside versus cephalosporin
Ten studies compared clindamycin plus aminoglycoside versus
cephalosporin in mild-moderate PID (Sweet 1985; Walters 1990)
or severe PID (Roy 1985; Sweet 1985; Soper 1988;Martens 1990;
Roy 1990; Walters 1990; Landers 1991; Maria 1992; Hemsell
1994; Balbi 1996). Studies from Sweet 1985 and Walters 1990
had both populations with mild-moderate and severe PID, thus
they were used in both analyses.
Primary outcomes
5.1. Effectiveness
5.1a. Clinical cure in mild-moderate pelvic inflammatory
disease
We analyzed two studies for clinical cure in mild-moderate PID
(Sweet 1985; Walters 1990). There was no clear evidence of a dif-
ference between these regimens in rates of cure for mild-moderate
PID (RR 1.02, 95% CI 0.95 to 1.09; 150 women; 2 studies; I2 =
0%, low-quality evidence) (Analysis 5.1; Figure 9).
Figure 9. Forest plot of comparison: 5 Regimens containing clindamycin plus aminoglycoside versus
cephalosporin, outcome: 5.1 Effectiveness of cure in mild-moderate PID.
5.1b. Clinical cure in severe pelvic inflammatory disease
We included 10 studies in the analysis of clinical cure in severe
PID (Roy 1985; Sweet 1985; Soper 1988; Martens 1990; Roy
1990; Walters 1990; Landers 1991; Maria 1992; Hemsell 1994;
Balbi 1996). There was no clear evidence of a difference between
these regimens in rates of cure of severe PID (RR 1.00, 95% CI
0.95 to 1.06; 959 women; 10 studies; I2 = 21%; moderate-quality
evidence) (Analysis 5.2; Figure 10).
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Figure 10. 5.2 Effectiveness of cure in severe PID in regimens containing clindamycin plus aminoglycoside
versus cephalosporin.
5.2. Adverse events
5.2.1. Antibiotic-related adverse effects leading to
discontinuation of therapy
We included 10 studies in the analysis of antibiotic-related ad-
verse effects leading to discontinuation of therapy (Roy 1985;
Sweet 1985; Soper 1988; Martens 1990; Roy 1990;Walters 1990;
Landers 1991; Maria 1992; Hemsell 1994; Balbi 1996). There
was no clear evidence of a difference between groups in adverse
effects leading to discontinuation of treatment (RR 0.78, 95% CI
0.18 to 3.42; 1172 women; 10 studies; I2 = 0%; very low-quality
evidence) (Analysis 5.3).
Data are depicted in Summary of findings 5.
Secondary outcomes
5.3. Microbiological clearance of chlamydia
Five studies reported chlamydia clearance (Sweet 1985; Roy 1990;
Walters 1990; Maria 1992; Balbi 1996). Cure occurred in 53/
56 women in the cephalosporin group (94.6%, 95% CI 85% to
98%) and in 75/78 women in the clindamycin plus aminoglyco-
side group (96%, 95% CI 89% to 99%).
5.4. Microbiological clearance of gonorrhoea
Five studies reported gonorrhoea clearance (Sweet 1985; Roy
1990; Walters 1990; Maria 1992; Balbi 1996). Cure occurred
in 96/96 women in the clindamycin plus aminoglycoside group
(100%, 95% CI 96% to 100%) and 115/117 women in the
cephalosporin group (98%, 95% CI 94% to 99%).
5.5. Laparoscopic evidence of resolution of pelvic
inflammatory disease based on physician opinion
We found no data for laparoscopic evidence of resolution of PID.
5.6. Length of stay (for inpatient care).
Seven studies did not provide enough data for analysis of length
of hospital stay (Roy 1985; Sweet 1985; Roy 1990; Walters 1990;
Landers 1991; Maria 1992; Balbi 1996). Three studies provided
the mean and standard deviations of hospital stay, or range of days
(Soper 1988; Martens 1990; Hemsell 1994). The mean length of
stay for the cephalosporin group varied from 5.8 days to 9.6 days
(range 3 days to 18 days) in the clindamycin plus aminoglycoside
group and the mean days of in hospital days varied from 5.8 days
to 9.8 days (range from 2 days to 25 days).
5.7. Rate of fertility
We found no data for rate of fertility.
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Other analyses
We were unable to conduct our planned subgroup analyses due to
insufficient data in the included studies.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Quinolone compared to cephalosporins for pelvic inflammatory disease
Population: women with PID
Setting: hospital ward or outpat ient clinic
Intervention: quinolone
Comparison: cephalosporins
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of women
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with
cephalosporins
Risk with quinolone
Clinical cure according
to criteria established
by study authors
M ild-moderate PID
Follow-up: range 14-28
days
198/ 225
880 per 1000
214/ 234
915 per 1,000
(871 to 944)
RR 1.04
(0.98 to 1.10)
NNTB 11
to
NNTH 46
459
(3 RCTs)
⊕⊕©©
Low 1,2
-
Clinical cure according
to criteria established
by study authors
Severe PID
Follow-up: range 14-28
days
106/ 160
643 per 1000
107/ 153
700 per 1000
(622 to 766)
RR 1.06
(0.91 to 1.23)
NNTB 7
to
NNTH 15
313
(2 RCTs)
⊕⊕©©
Low 1,2
-
Adverse events: any
ant ibiot ic-related ad-
verse event leading to
discont inuat ion of ther-
apy
2/ 384
5 per 1000
5/ 388
12 per 1000
(5 to 29)
RR 2.24
(0.52 to 9.72)
NNTB 40
to
NNTH 129
772
(5 RCTs)
⊕©©©
Very low 1,3
2 of the 5 RCTs (502
women) did not con-
tribute to this analysis
because the authors re-
ported no events
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Follow-up: mean 14
days
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; PID: pelvic
inf lammatory disease; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for serious risk of bias (poor report ing of methods and high or unclear risk of performance and
detect ion bias in one or more studies).
2 Downgraded one level for serious imprecision: conf idence intervals compatible with benef it in one or both groups, or with
no dif ference between the groups.
3 Downgraded two levels for very serious imprecision: conf idence intervals compatible with benef it in one or both groups, or
with no dif ference between the groups, only seven events overall.
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Nitroimidazole compared to no nitroimidazole for pelvic inflammatory disease
Population: women with PID
Setting: hospital ward or outpat ient clinic
Intervention: nitroim idazole
Comparison: no use of nitroim idazole
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of women
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no use of ni-
troimidazole
Risk with nitroimida-
zole
Clinical cure according
to criteria established
by study authors
M ild-moderate PID
Follow-up: range 14-28
days
925/ 1214
762 per 1000
949/ 1213
782 per 1000
(758 to 804)
RR 1.01
(0.93 to 1.10)
NNTB 19
to
NNTH 77
2427
(5 RCTs)
⊕⊕⊕©
M oderate 1,2
-
Clinical cure according
to criteria established
by study authors
M ild-moderate PID
Follow-up: range 14-28
days
Sensit ivity analysis re-
stricted to studies at
low risk of bias
452/ 606
746 per 1000
470/ 595
790 per 1000
(755 to 820)
RR 1.06
(0.98 to 1.15)
NNTB 11
to
NNTH 266
1201
(2 RCTs)
⊕⊕⊕⊕
High
-
Clinical cure according
to criteria established
by study authors
Severe PID
Follow-up: range 14-28
days
573/ 689
832 per 1000
558/ 694
804 per 1000
(772 to 831)
RR 0.96
(0.92 to 1.01)
NNTB 15
to
NNTH 76
1383
(11 RCTs)
⊕⊕⊕©
M oderate 1
-
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Adverse events: any
ant ibiot ic-related ad-
verse event leading to
discont inuat ion of ther-
apy
Follow-up: mean 14
days
34/ 1911
18 per 1000
33/ 1910
17 per 1000
(12 to 24)
RR 1.00
(0.63 to 1.59)
NNTB 110
to
NNTH 125
3821
(16 RCTs)
⊕⊕©©
Low 1,3
10/ 16 studies (1088
women) did not con-
tribute data to the
analysis because the
authors reported no
events
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; PID: pelvic
inf lammatory disease; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for serious risk of bias (poor report ing of methods and high or unclear risk of performance and
detect ion bias in one or more studies).
2 Substant ial inconsistency (I2 = 50%). Not downgraded because all inconsistency related to a single small study (30 women)
which barely inf luenced the overall est imate.
3 Downgraded one level for serious imprecision: conf idence intervals compatible with benef it in one or both groups, or with
no dif ference between the groups, only 68 events overall.
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Clindamycin plus aminoglycoside compared to quinolone for pelvic inflammatory disease
Population: women with PID
Setting: hospital ward or outpat ient clinic
Intervention: clindamycin + aminoglycoside
Comparison: quinolone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of women
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with quinolone Risk with clindamycin +
aminoglycoside
Clinical cure according
to criteria established
by authors
M ild-moderate PID
Follow-up: median 14
days
10/ 10
1000 per 1000
13/ 15
867 per 1000
(621 to 962)
RR 0.88
(0.69 to 1.13)
NNTB 3
to
NNTH 6
25
(1 RCT)
⊕©©©
Very low 1,2
-
Clinical cure according
to criteria established
by authors
Severe PID
Follow-up: median 14
days
60/ 75
800 per 1000
62/ 76
816 per 1000
(714 to 887)
RR 1.02
(0.87 to 1.19)
NNTB 7
to
NNTH 9
151
(2 RCTs)
⊕⊕©©
Low3,4
-
Adverse events: any
ant ibiot ic-related ad-
verse event leading to
discont inuat ion of ther-
apy
Follow-up: mean 14
days
4/ 80
50 per 1000
0/ 83
0 per 1000
(0 to 44)
RR 0.21
(0.02 to 1.72)
NNTB 8
to
NNTH 273
163
(3 RCTs)
⊕©©©
Very low 1,2
1/ 3 RCTs (25 women)
did not contribute data
to the analysis because
the authors reported no
events
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* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; PID: pelvic
inf lammatory disease; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels for very serious risk of bias: single unblinded study with poor report ing of methods.
2 Downgraded two levels for serious imprecision (though further downgrading not possible): conf idence intervals compatible
with benef it in one or both groups, or with no dif ference between the groups, very few events overall.
3 Downgraded one level for serious risk of bias (poor report ing of methods and high or unclear risk of performance and
detect ion bias in both studies).
4 Downgraded one level for serious imprecision: conf idence intervals compatible with benef it in one or both groups, or with
no dif ference between the groups.
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Clindamycin plus aminoglycoside compared to cephalosporin for pelvic inflammatory disease
Population: women with PID
Setting: hospital ward or outpat ient clinic
Intervention: clindamycin + aminoglycoside
Comparison: cephalosporin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of women
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with
cephalosporin
Risk with clindamycin
plus aminoglycoside
Clinical cure according
to criteria established
by authors
M ild-moderate PID
Follow-up: median 14
days
69/ 72
958 per 1000
76/ 78
974 per 1000
(911 to 993)
RR 1.02
(0.95 to 1.09)
NNTB 11
to
NNTH 19
150
(2 RCTs)
⊕⊕©©
Low 1,2
-
Clinical cure according
to criteria established
by authors
Severe PID
Follow-up: median 14
days
441/ 525
840 per 1000
364/ 434
838 per 1000
(801 to 870)
RR 1.0
(0.95 to 1.06)
NNTB 21
to
NNTH 22
959
(10 RCTs)
⊕⊕⊕©
M oderate 1
-
Adverse events: any
ant ibiot ic-related ad-
verse event leading to
discont inuat ion of ther-
apy
Follow-up: mean 14
days
3/ 670
4 per 1000
3/ 502
6 per 1000
(2 to 17)
RR 0.78
(0.18 to 3.42)
NNTB 75
to
NNTH 126
1172
(10 RCTs)
⊕©©©
Very low 1,3
7/
10 RCTs (617 women)
did not contribute data
to the analysis reported
because the authors re-
ported no events
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* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its 95
CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; PID: pelvic
inf lammatory disease; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for serious risk of bias (poor report ing of methods and high or unclear risk of performance and
detect ion bias in one or more studies).
2 Downgraded one level for serious imprecision, small overall sample size.
3 Downgraded two levels for serious imprecision (though further downgrading not possible): conf idence intervals compatible
with benef it in one or both groups, or with no dif ference between the groups, only six events overall.
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D I S C U S S I O N
Summary of main results
We included 37 trials with 6348 women in the review. We found
no clear evidence of a difference between any of the regimens
studied in terms of effectiveness or safety.
The only comparison that clearly suggested a difference between
the interventions was the sensitivity analysis of cases of mild-mod-
erate PID for the comparison macrolide (azithromycin) versus
tetracycline (doxycycline). When we limited analysis to the single
study at low risk of bias, moderate-quality evidence suggested that
azithromycinwas superior to doxycycline in achieving clinical cure
(Summary of findings for the main comparison).
Some guidelines have recommended the use of nitroimidazoles for
treating PID (Ross 2007; Workowski 2015). We found no con-
clusive evidence of a difference between the use or not of nitroim-
idazoles (metronidazole) in rates of cure in either mild-moderate
or severe PID. There was also no clear evidence of a difference in
rates of adverse effects.
Overall completeness and applicability of
evidence
Although we conducted comprehensive searches to identify all
published and unpublished RCTs, this systematic review included
trials at high risk of bias and consequently with low confidence
in the estimate of effect (see Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3;
Summary of findings 4; Summary of findings 5). When we used
ITT analysis, there was substantial heterogeneity in the azithro-
mycin trial results, which may limit our conclusions.
Data were lacking for several of our secondary outcomes. None
of the included studies reported data on fertility or laparoscopic
evidence of PID resolution, and data were very scant on length of
stay.
The applicability of the evidence to the target population (women
of reproductive age diagnosed with PID) was broad because the
included trials were conducted in different clinical settings and
implemented varying diagnostic approaches. Additionally, the in-
terventions analyzed in the review are available in various clin-
ical settings and represent the most frequently used therapeutic
schemes in current clinical practice. Given these factors, we con-
sider that the evidence identified applies to a wide range of women
with PID varying in disease severity, age, geographical location,
and diagnostic criteria, which provides external validity.
PID can be life or fertility threatening, and treatment is routinely
started before laboratory cultures or laparoscopic confirmation.
In some cases, women were subsequently diagnosed with another
condition; however, we included all women in our ITT analysis,
in accordance with our review protocol.
Quality of the evidence
Most of the 37 included studies had unclear or high risk of bias
in most domains, and only three were at low risk of bias in most
domains (Ross 2006; Savaris 2007; Judlin 2010a). The remaining
studies had a number of limitations, for instance, 25 trials did not
clearly define randomization, and there was potential performance
and detection bias in 20 studies (Figure 3).
The overall quality of the evidence ranged from very low to high,
the main limitations being serious risk of bias (due to poor re-
porting of study methods and lack of blinding), serious inconsis-
tency, and serious imprecision. There was substantial heterogene-
ity in the comparison between azithromycin and doxycycline (I2
= 72%; Figure 5) and in the comparison of nitroimidazole versus
no nitroimidazole (I2 = 60%; Figure 7). Imprecision was related to
suboptimal sample sizes and the low number of studies for some
comparisons.
The quality of evidence for the outcomes analyzed is provided in
the ’Summary of findings’ tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5). The only high-
quality evidence was for the sensitivity analysis regarding the use
(or not) of nitroimidazole. Therewasmoderate-quality evidence in
the sensitivity analysis regarding the use of azithromycin in mild-
moderate cases of PID, in comparisons between the use or not
of nitroimidazole for curing mild-moderate or severe PID, and
in comparisons between clindamycin plus aminoglycoside versus
cephalosporins for curing severe PID.
For all other comparisons, the evidence was low or very lowquality.
Potential biases in the review process
An important limitation of this systematic reviewwas the potential
for measurement bias introduced by using the investigators’ defi-
nitions of cure. This approach was necessary because of the wide
variation in methods used and lack of a widely accepted objective
outcome measure. The short-term follow-up of most of the stud-
ies prevented the identification of long-term sequelae. In addition,
the inaccuracy of clinical diagnosis for PID and the wide variety
of assessment criteria used for clinical cure may have reduced the
power of the analysis to detect a significant effect.
Some studies identified PID and endometritis separately but these
were pooled for our analysis.
Agreements and disagreements with other
studies or reviews
One previous meta-analysis, published in 1993, formed the ba-
sis for the CDC guidelines (Walker 1993). The authors reported
pooled clinical cure rates ranging from 75% to 94%, which is
similar to our updated review with overall rate of cure of 81%.
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Therefore, our results support the updated 2015 CDC guide-
lines (Workowski 2015) and the International Union against Sexu-
ally Transmitted Infections (IUSTI)/BASHH (Judlin 2010b; Ross
2014a), but not the inclusion of nitroimidazoles in treatment reg-
imens.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no conclusive evidence that one regimen is safer or more
effective than any other for the cure of PID, and there is no clear
evidence for the use of nitroimidazoles (metronidazole) compared
to use of other drugs with activity over anaerobes. Moderate-qual-
ity evidence from a single study at low risk of bias suggests that
a macrolide (azithromycin) may be more effective than a tetra-
cycline (doxycycline) for curing mild-moderate PID. Our review
considers only the drugs that are currently used and mentioned
by the US Centers for Disease Control and Prevention (CDC).
Implications for research
There is a need for high-quality randomized controlled trials fol-
lowing CONSORTguidance to assess treatments for women with
PID, particularly further trials comparing oral azithromycin ver-
sus oral doxycycline and the use of nitroimidazoles. The lack of a
consistent outcome measure to assess response to therapy is a ma-
jor limitation and there is a clear need for core outcome measures
to be developed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Apuzzio 1989
Methods Randomized controlled trial.
Participants Inclusion criteria: women admitted to the University Hospital of the University of
Medicine and Dentistry of New Jersey from February 1987 to October 1988 with the
diagnosis of either postpartum endometritis or acute salpingitis. Diagnosis of uncompli-
cated PID was based on the clinical criteria described by Hager and colleagues (Hager
1989).
Exclusion criteria: history of allergy to the study drugs or received any antibiotic in
the 2-week period prior to the study (exclusive of prophylactic antibiotics for caesarean
delivery)
Number of women randomized: 25 for PID
Number of women analyzed: group A: 10; group B: 15.
Number of withdrawals/exclusions/loss to follow-up and reasons: .none
Number of centres: 1.
Age (years): group A: 23.2; group B: 23.2.
Country: US.
Interventions Group A: ciprofloxacin 300 mg IV every 12 h; treatment continued for 3-5 days until
the woman was asymptomatic for 24 h. Upon discharge from hospital, women received
oral antibiotics to complete 10-14 days of ciprofloxacin 750 mg PO twice daily
Group B: clindamycin 900 mg IV every 8 h + gentamicin 1.5 mg/kg IV every 8 h. Upon
discharge from the hospital, the women received oral antibiotics to complete 10-14 days
of clindamycin 450 mg PO every 6 h
Outcomes Primary outcome: treatment success, defined as women asymptomatic for 24 h.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women randomly assigned to receive clindamycin +
gentamicin or ciprofloxacin intravenously
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
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Apuzzio 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk 25 women with uncomplicated PID randomized. 10
women received ciprofloxacin and 15 women received
clindamycin + gentamicin. 1 woman prescribed clin-
damycin + gentamicin was not available because triple
therapy was initially started. This woman was included
in the analysis as treatment success. The authors did not
clarify that
Arredondo 1997
Methods Randomized, double-blind, comparative study.
Participants Inclusion criteria: women aged 18-55 years with clinical diagnosis of mild or moderate
PID, as confirmed by laparoscopy graded according to the methods of Hager and col-
leagues (Hager 1983); and Soper (Soper 1991).
Exclusion criteria:observable pelvicmass; presentedwith laparoscopic evidence of severe
PID; pregnant or breastfeeding; allergic to clindamycin, ciprofloxacin, ceftriaxone, or
doxycycline; required other antibiotic therapy for non-protocol reasons; had had pelvic
or abdominal surgery in the 30 days prior to admission (except emergency exploratory
laparoscopy resulting in a primary diagnosis of PID that did not require pelvic cleanup);
had concomitant disease that could have affected the evaluation of response to protocol
therapy (such as inflammatory bowel disease or significant renal or hepatic disease);
had a history of colitis; were known to have frequent sexual contacts with multiple
partners; were seropositive for syphilis; had severemedical condition(s) (e.g. neoplasms or
haematological malignancy); had taken≥ 2 antibiotics within 72 h before evaluation for
enrolment in the study; had received any investigational drug 30 days before evaluation
for enrolment; or had been previously enrolled in the study
Number of women randomized: 69 in each group.
Number of women analyzed: .69 in each group
Number of withdrawals/exclusions/loss to follow-up and reasons: 2 in the clin-
damycin+ciprofloxacin group; 1 chose to discontinue because she was asymptomatic and
1 withdrew because of a side effect. In the ceftriaxone+doxycycline group, 1 withdrew
because of a side effect, 1 was lost to follow-up and 1 was withdrawn because of receiving
additional antibiotic treatment for syphilis after initiation of study medication
Number of centres: 6; Chile (1 centre), Peru (2 centres), Colombia (2 centres), and
Mexico (1 centre)
Age (mean) (years): group A: 28.9; group B: 30.7.
Country:Mexico
Interventions Group A: clindamycin 300 mg (2 capsules 3 times daily) + ciprofloxacin (250 mg, 1
tablet twice daily) for 14 days and placebo IM (for an equivalent of 1 dose of ceftriaxone)
Group B: ceftriaxone 250 mg IM (as a single dose) + doxycycline 100 mg (1 capsule
twice daily) and placebo (2 capsules 3 times daily for equivalent doses of clindamycin)
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Arredondo 1997 (Continued)
for 14 days
Outcomes Clinical cure defined by the absence of, or minimal, pelvic tenderness, temperature <
37.5 °C, and a WBC count of 10,000/mm3 , if a minimum of 4 days of treatment had
been completed. Clinical improvement defined as resolution of 2 of these 3 symptoms.
Failure when 1 of the following circumstances was noted after at least 48 h of protocol
therapy: signs and symptoms remained unchanged or worsened (during the first 72 h of
therapy)
Microbiological cure defined as eradication of N gonorrhoeae or C trachomatis (or both)
from clinically cured women. Failure defined as persistence of 1 or both of these 2
organisms or, in the case of clinical improvement or failure, the presence of endocervical
pathogens. Superinfection defined as the isolation of ≥ 1 new pathogens
Adverse effects leading to discontinuation of treatment.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk All eligible women randomized to 1 of the
treatment groups.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo medication was added as necessary
to complete the double-blind design. All
oral medication was encapsulated to ensure
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo medication was added as necessary
to complete the double-blind design. All
oral medication was encapsulated to ensure
blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
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Aicio lu 2013
Methods Randomized, parallel-group study.
Participants Inclusion criteria: women aged 14-45 years with acute uncomplicated PID based on
presence of all the following symptoms and signs: pelvic discomfort, direct lower abdom-
inal tenderness, adnexal and cervical motion tenderness on bimanual vaginal examina-
tion, and pelvic pain for < 30 days, as well as ≥ 1 of the following signs: pyrexia (rectal,
tympanic, or oral temperature > 38.8 °C or axillary temperature > 37.5 °C), elevated
CRP > 6 mg/L, WBC > 10,500/mm3 , and a normal ultrasonographic scan.
Exclusion criteria: urinary tract infection; complicated PID (such as tubo-ovarian ab-
scess); endometriosis; pelvic pain > 30 days; history of antibiotic therapy within last
week; previous failure to adhere to antibiotic treatment; other causes of abdominopelvic
pain such as appendicitis, diverticulitis, or ovarian cysts; oral intolerance, defined as 1
episode of vomiting after the first oral medication administration; and delivery, abortion,
or surgery within the last month
Number of women randomized: 1156.
Number of women analyzed: group A: 578; group B: 578.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 18
women lost (oral intolerance n = 2; non-compliance n = 5; worsening of pain n = 3; tubo-
ovarian abscess n = 2; urinary tract infection n = 2; other n = 4); group B: 35 women lost
(oral intolerance n = 4; non-compliance n = 18; worsening of pain n = 2; tubo-ovarian
abscess n = 2; urinary tract infection n = 4; other n = 5)
Number of centres: 4.
Age (mean ± SD) (years): group A: 30.3 ± 3.7; group B: 29.3 ± 3.5.
Country: Turkey.
Interventions Group A: moxifloxacin 400 mg once daily for 14 days.
Group B: ofloxacin 400 mg twice daily + metronidazole 500 mg PO twice daily
Outcomes Clinical cure, microbiological cure, adverse effects.
Primary outcome: clinical cure, defined as a ≥ 60% reduction in the total pain score
at day 21 compared with baseline and the absence of pelvic discomfort and tenderness,
temperature < 37.8 °C, and WBC < 10,000/mm3 on day 21.
Notes Ethical approval: yes.
Informed consent: yes, women gave written informed consent.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random-numbers table.
Allocation concealment (selection bias) Low risk Assigned treatments written on cards and sealed in
secure opaque envelopes numbered in sequence
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Aicio lu 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Investigators not blinded to the procedure allo-
cation. Moxifloxacin group received just 1 tablet,
whereas ofloxacin + metronidazole group received
4 tablets daily. No placebo was added to mask
groups
Blinding of outcome assessment (detection
bias)
All outcomes
High risk 7 days after drug treatment at secondary visits (day
21), all women underwent a secondary evaluation
by the same physician who allocated women
Incomplete outcome data (attrition bias)
All outcomes
Low risk From 1156 women, 53 lost to follow-up.
Selective reporting (reporting bias) Low risk Trial registered in ClinicalTrial.gov
(NCT01799356).
Other bias Unclear risk Risk of potential bias unclear.
Balbi 1996
Methods Randomized controlled trial.
Participants Inclusion criteria: women with PID diagnosis based on all the following criteria: pelvic
pain, either spontaneous or at palpation; cervical motion tenderness; and adnexal pain
Exclusion criteria: aged < 16 year, current pregnancy, allergy to 1 of the medications
used in study or to penicillin, serum creatinine > 1.5 mg/dL, previous or current hepatic
disease, use of antibiotics in the last 7 days, in situ IUD
Number of women randomized: 78.
Number of women analyzed: 76; group A: 40; group B: 36.
Number of withdrawals/exclusions/loss to follow-up and reasons: 2, intolerance to
penicillin.
Number of centres: 1.
Age (mean ± SD) (years): group A: 25.3 ± 7.7.4; group B: 29.4 ± 7.8.
Country: Italy.
Interventions Group A: gentamicin, 2 mg/kg IV (attack dose), followed by 1.5 mg/kg IV every 8 h +
clindamycin 900 mg IV every 8 h for 4 days, followed by clindamycin 450 mg PO every
6 h for a total of 14 days of treatment
Group B: ceftazidime 1 g IV every 8 h + doxycycline 100 mg PO every 12 h for 4 days,
followed by doxycycline 100 mg PO every 12 h for a total of 14 days of treatment
Outcomes Primary outcome: clinical recovery, defined as: body temperature < 37 °C per 48 h,
disappearance of pelvic pain, no increase of eventual adnexal mass after 7 days of the end
of treatment
Secondary outcome: follow-up performed 30 days after treatment finished; endocervical
culture for N gonorrhoeae and C trachomatis and endometrial culture for C Trachomatis
performed in all positive cases at admission.
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Balbi 1996 (Continued)
Notes Ethical approval: not stated.
Informed consent: not stated.
Funding source: no funding stated or declaration of interest.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were randomly allocated into 2 treatment
groups.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/78 women excluded from analysis.
Selective reporting (reporting bias) Unclear risk Not stated.
Other bias Unclear risk Not stated.
Bevan 2003
Methods Randomized, open-label, comparative, multicentre, and multinational trial
Participants Inclusion criteria: aged ≥ 18 years, fulfilling Hager’s criteria for a clinical diagnosis of
acute PID (Hager 1983), and requiring hospitalization for treatment. Diagnosis of acute
PID confirmed by laparoscopy unless impossible due to need for immediate treatment
Exclusion criteria: palpable tubo-ovarian abscess (i.e. ultrasound diameter≥ 5 cm); use
of additional antimicrobial therapy for a concurrent infection; use of antibiotic therapy
during the preceding 2 weeks; terminal illness; immunosuppression; impaired gastroin-
testinal function or absorption (or both); hepatic or renal impairment; known allergy
to macrolides, tetracycline, metronidazole, penicillin, cephalosporins, or clavulanic acid;
use of oral hypoglycaemic drugs, ergot, dicoumarin anticoagulants, carbamazepine, ci-
closporin, digoxin, or theophylline; and known drug addiction, alcoholism, or taking of
recreational drugs
Number of women randomized: 310.
Number of women analyzed: 309; group A: 106; group B: 107; group C: 96.
Number of withdrawals/exclusions/loss to follow-up and reasons: 10 patients were
excluded from the analysis at end of treatment because of the following protocol viola-
tions: did not receive
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Bevan 2003 (Continued)
study medication (n = 1); inappropriate primary diagnosis (n = 2); concomitant an-
tibacterial treatment (n = 1); no signs/symptoms recorded at day evaluation (n = 1); and
missing data or mistimed evaluation (n = 5)
Number of centres: multiple, but the authors did not specify how many.
Age (mean (range)) (years): group A: 28.4 (18-54); group B: 27.6 (18-46); group C:
27.6 (17-54)
Country: UK and others that were not stated.
Interventions Group A: azithromycin 500 mg IV single dose, days 2-7: 250 mg PO once daily or days
1-2: azithromycin 500 mg IV once daily; days 3-7: 250 mg PO once daily
Group B: as group A + day 1: metronidazole 500 mg IV 3 times daily or 400 mg PO 3
times daily, days 2-12: metronidazole 400 mg PO3 times daily or days 1-2: azithromycin
500 mg IV once daily; days 3-7: 250 mg PO once daily plus day 1-2: metronidazole 500
mg IV 3 times daily, or 500 mg PO 3 times daily. Days 3-12: metronidazole 500 mg PO
3 times daily or days 1-21: metronidazole 500 mg PO 3 times daily
Group C: day 1: metronidazole 500 mg IV 3 times daily, or metronidazole 400 mg PO
3 times daily; day 2-12: metronidazole 400 mg PO 3 times daily + days 1-14: cefoxitin 2
g IV or IM 4 times daily + day 1: probenecid 1 g PO single dose or day 1-21: doxycycline
100 mg PO twice daily + day 1-5: amoxicillin/clavulanate 1 g IV + times daily; day 6-
21 amoxicillin/clavulanate 500 mg PO 3 times daily
Outcomes Clinical response to treatment: cure, resolution of all baseline signs and symptoms;
improvement, lessening of the baseline signs and symptoms or absence of ≥ 1, but
not all, of the baseline findings; or failure, no improvement or deterioration of baseline
condition. Successful clinical outcome defined as cure or improvement. Assessment on
day 15 (9-26 inclusive) and at follow-up (day 35-44)
Microbiological outcome: eradication, absence of the baseline isolate(s); persistence,
presence of baseline isolate(s); or superinfection, presence of a micro-organism different
from that found at baseline
Notes Ethical approval: yes “European Ethical ReviewCommittee and by local hospital ethical
committees.”
Informed consent: yes, prior to entry into either study, written informed or witnessed
oral consent was obtained from each woman
Source of funding: not stated, but 1 the authors was from Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women randomized to 1 of 3 treatment
groups.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
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Bevan 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate (< 20%).
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Trial had support of pharmaceutical indus-
try. 1 casemissing from the analysis and not
specified in the report
Buisson 1989
Methods Randomized controlled trial.
Participants Inclusion criteria: women with PID associated or not associated with endometritis con-
firmed by laparoscopy according to the clinical criteria described byHager and colleagues
(Hager 1989).
Exclusion criteria:knownallergy to betalactamics, pregnant, renal and liver insufficiency
Number of women randomized: 82.
Number of women analyzed: group A: 42; group B: 40.
Number of withdrawals/exclusions/loss to follow-up and reasons: 1 abandoned the
amoxicillin-clavulanic acid after knowing that the bacteria (K. pneumoniae) was resistant
to the antibiotic. One stopped amoxicillin-clavulanic acid after 6 days of treatment due
to no clinical improvement and she was switched to group B; In group B, one patient
stopped the treatment due to side-effect (Quincke edema)
Number of centres: 8.
Age (mean (range)) (years): group A: 27.7 (18-46); group B: 28.7 (15-49).
Country: France.
Interventions Group A: amoxicillin-clavulanic acid 1 g IV every 8 h for at least 48 h, then 1.5-2 g PO
twice daily. Mean length of treatment 19 days, never less than 14 days
Group B: amoxicillin 3-4 g IV per 24 h, mean 4 days, then 1.5-2 g PO daily. Mean
length of treatment 17 days + aminoside (chosen by researcher’s preference) 3-5 mg/kg
IM per 24 h 2 or 3 times daily depending of the aminoside, mean length of treatment
7 days + metronidazole 1 or 1.5 g IV or suppository daily
For each case, a secondary prescription for a tetracycline 200 mg per 24 h was given,
either immediately if results of laparoscopy or other investigations justified it, or later
on positive chlamydia serology. Length of this treatment 3-4 weeks as decided by the
researcher
Outcomes Primary outcomes: clinical cure; defined as absence of fever, pain, and previously ob-
served adnexal masses at 5-8 weeks’ follow-up; adverse events leading to discontinuation
of treatment
Secondary outcome: none reported.
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Buisson 1989 (Continued)
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The choice of treatment fixed by randomization.
Allocation concealment (selection bias) Unclear risk The choice of treatment fixed by randomization.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/82 women lost to follow-up.
Selective reporting (reporting bias) Unclear risk No protocol found.
Other bias Unclear risk Not stated.
Burchell 1987
Methods Randomized controlled trial.
Participants Inclusion criteria: 40 women with PID established by blood sampling, laparoscopic,
follow-up clinical evaluations, and taking of microbiological specimens for culture done
by same physician to ensure uniformity. Women had laparoscopic examination and
microbiological cultures to confirm the clinical diagnosis of acute PID
Exclusion criteria: general peritonitis or with abdominal distension and absent bowel
sounds; large pelvicmasses extending into the abdomen; toxic; in poor general condition;
pregnant (e.g. postabortal); and antibiotics in the 14 days before presentation
Number of women randomized: 30 women, 10 in each group.
Number of women analyzed: 30 women, 10 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 10 women ex-
cluded because laparoscopic examination and microbiological cultures did not confirm
the clinical diagnosis of acute PID
Number of centres: not stated.
Age (years): not stated.
Country: South Africa.
54Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Burchell 1987 (Continued)
Interventions Group A: doxycycline infusion 200 mg in 200 mL 5% dextrose over 2 h + doxycycline
100 mg after 24 h. The course was completed with oxytetracycline 250 mg every 6 h for
14 days
Group B: ampicillin + metronidazole every 6 h 1 g IV and then 500 mg PO every 6 h
for 14 days
Group C: tetracycline + metronidazole with 3 × 1 g suppositories every 8 h and then
400 mg PO every 8 h for 14 days
Outcomes Primary outcome: clinical cure.
Notes Ethical approval: not stated.
Informed consent: yes, informed consent was obtained from all women.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk No study group characteristics reported.
Ciraru-Vigneron 1986
Methods Randomized controlled trial.
Participants Inclusion criteria: severe PID, defined as signs of fever, pain. Local signs (adnexal mass)
, discovery of pathogen, leukocytosis, elevated ESR, pelvic ultrasound, and possibly
laparoscopy
Exclusion criteria: not stated.
Number of women randomized: 44; 22 in each group.
Number of women analyzed: 44; 22 in each group.
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Number of withdrawals/exclusions/loss to follow-up and reasons: only 20% of
women seen.
Number of centres: 1.
Age (years): not stated.
Country: France.
Interventions Group A: amoxicillin-clavulanic acid while in hospital, 4 g per 24 h, first by IV, then
PO once symptoms improved. At discharge, amoxicillin-clavulanic acid PO if chlamydia
serology was negative; if positive for chlamydia, doxycycline prescribed for 3 weeks (dose
not stated)
GroupB: ampicillin 6 g per 24 h IV + gentamicin 160mgper 24 h IM+metronidazole 1.
5 g per 24 h IV; when switched to oral administration, ampicillin replaced by amoxicillin
3 g per 24 h + metronidazole 1.5 g per 24 h PO and gentamicin 160 mg per 24 h IM for
minimum of 7 days. At discharge, amoxicillin-clavulanic acid PO if chlamydia serology
negative; if positive for chlamydia, doxycycline for 3 weeks (dose not stated)
Outcomes Primary outcomes: clinical cure, defined by no fever, reduction of pain, and normal
WBC count at discharge and in 30 days; adverse events leading to discontinuation of
treatment
Secondary outcomes: microbial cure of N gonorrhoeae and C trachomatis; length of
hospital stay.
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized study.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
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Other bias Unclear risk Assumed that assessment of ’cure’, ’improvement,’ and
’failure’ performed during hospitalization or at discharge
Follow-up at 30 days; only 20% in each group seen. In
those women, no secondary adverse events seen
Ciraru-Vigneron 1989
Methods Randomized controlled trial.
Participants Inclusion criteria: not stated.
Exclusion criteria: required systemic or local antibiotic therapy other than those specified
in the protocol; pregnant or likely to become pregnant; or allergic to penicillins or
cephalosporins
Number of women randomized: 165 women; group A: 78; group B: 87.
Number of women analyzed: 152 women; group A: 70; group B: 82.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 8; group
B: 5 due to poor compliance.
Number of centres: 8.
Age (mean) (years): group A: 26.9; group B: 25.1.
Country: France.
Interventions Group A: amoxicillin 1 g IV + clavulanic acid 200 mg (Augmentin 1.2 g), 3 or 4 times
daily until clinical and laboratory findings improved, after which 4-6 tablets containing
amoxicillin 500 mg + clavulanic acid 125 mg (Augmentin 625 mg) per tablet
Group B: amoxicillin or ampicillin 3-4 g daily, with an aminoglycoside (gentamicin 160
mg, dibekacin 150 mg, or tobramycin 150 mg) + metronidazole 1.5 g daily parenterally.
Subsequent conversion was to oral combination of amoxicillin or ampicillin 2-3 g +
metronidazole 1-1.5 g daily
Outcomes Primary outcomes: excellent response defined as resolution of physical findings with
continued improvements in laboratory values; favourable response equate with a
favourable course, allowing the persistence of ≥ 1 clinical signs or abnormal laboratory
values (or both); failure defined as absence of therapeutic efficacy or of a favourable
course after at least 6 days of therapy that a change in management, either surgery or an
alternative antibiotic treatment was warranted
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 152/165 women included in the analysis.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Crombleholme 1986
Methods Randomized controlled trial.
Participants Inclusion criteria: severe acute PIDwith peritonitis, tubo-ovarian abscess, endometritis,
and pelvic cellulitis
Exclusion criteria: not stated.
Number of women randomized: 39; group A: 20; group B: 19.
Number of women analyzed: 39; group A: 20; group B: 19.
Number of withdrawals/exclusions/loss to follow-up and reasons: not stated.
Number of centres: not stated.
Age (years): not stated.
Country: not stated.
Interventions Group A: sulbactam 1 g + ampicillin 2 g IV every 6 h.
Group B: metronidazole 15 mg/kg loading followed by 7.5 mg/kg IV every 6 h and
gentamicin 1.5 mg/kg IV every 8 h
Antibiotics in both groups continued for minimum of 5 days.
Outcomes No relevant outcomes reported for our analysis because the outcomes were not separately
reported for the different diagnoses within the study groups. Authors stated clinical cure
occurred in 19/20 women in group A and 16/19 women in group B
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
2 cases of posthysterectomy pelvic cellulitis were included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Crombleholme 1987
Methods Randomized controlled trial.
Participants Inclusion criteria: hospitalized women aged ≥ 18 years with a documented or clinical
diagnosis of mixed aerobic-anaerobic PID
Exclusion criteria: pregnant or lactating; allergy to penicillins, cephalosporins, amino-
glycosides, or metronidazole; impaired renal function (serum creatinine > 1.8 mg/100
mL); family history of glycogen storage disease or recurrent hypoglycaemia; history of
unstable cardiovascular, hepatic, renal, or neurological disease
Number of women randomized: 44; 22 in each group.
Number of women analyzed: 42; 21 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 1 women in group
A with a clinical diagnosis of PID and a right adnexal mass excluded. Laparoscopy
revealed a right ovarian cyst, no visual evidence of infection, and essentially no growth
from cervical and endometrial cultures. 1 woman in group B with a clinical diagnosis of
PID excluded; she left the hospital against medical advice on the third hospital day
Number of centres: 1.
Age (mean ± SD) (years): group A: 27.7 ± 6.9; group B: 29.0 ± 12.1.
Country: US.
Interventions Group A: ampicillin 2 g + sulbactam 1 g IV every 6 h.
Group B: metronidazole 15 mg/kg IV every 6 h + gentamicin 1.5 mg/kg IV every 8 h
Therapy continued until women became afebrile and were without clinical signs of
infection for 48 h or until clinical judgement dictated cessation of therapy
Range of treatment 3-11 days.
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Outcomes Primary outcome: clinical cure defined as absence of fever, without clinical signs of
infections for 48 h or until clinical judgement
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman missing in each group.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Crombleholme 1989
Methods Randomized controlled trial.
Participants Inclusion criteria: women aged ≥ 18 years admitted to San Francisco General hospital
with a diagnosis of acute PID according to established criteria: history of lower abdominal
pain and direct lower abdominal tenderness with or without rebound; tenderness with
motion of the cervix and uterus; and adnexal tenderness.≥ 1 of the following: endocervix
positive for Gram-negative intracellular diplococci or direct fluorescent antibody test
revealing C trachomatis; elevated ESR; temperature > 38 °C; leukocytosis > 10,500 white
blood cells/mm3; purulent material (WBCs and bacteria) from the peritoneal cavity by
culdocentesis; or a pelvic abscess or inflammatory complex on bimanual examination or
by sonography
Exclusion criteria: history of allergy to any of the study drugs; mild infections not
requiring parenteral antimicrobial therapy; pregnancy or lactation; severe underlying
terminal illness; need for concomitant antimicrobial with a spectrum of activity similar
to that of study drug; or severe impairment of renal function (creatinine level > 2 mg/
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dL or creatinine clearance < 50 mL/minute)
Number of women randomized: 80; 40 in each group.
Number of women analyzed: 80; 40 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: none reported.
Number of centres: 1.
Age (mean ± SD) (years): group A: 25.7 ± 4.8; group B: 25.3 ± 6.2.
Country: US.
Interventions Group A: ciprofloxacin 300 mg IV every 12 h for 2-5 days, with ≥ 2 days of parenteral
therapy and 48 h without fever before switching to ciprofloxacin 750 mg PO every 12
h, to complete a 14-day course
Group B: clindamycin 600 mg IV every 6 h + 1 mg/kg IV every 8 h after ≥ 4 days of
parenteral gentamicin and 48 h without fever before switching to clindamycin 300 mg
PO every 6 h, to complete a 14-day course
Outcomes Primary outcome: clinical cure at 3 days: improvement in clinical signs and symptoms
Secondary outcomes: microbial cure of C trachomatis and N gonorrhoeae.
Notes Ethical approval: yes, women gave written informed consent as approved by the Com-
mittee of Human Research of the University of California, San Francisco
Informed consent: yes, women gave written informed consent as approved by the Com-
mittee of Human Research of the University of California, San Francisco
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
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Methods Randomized controlled trial.
Participants Inclusion criteria: women aged > 18 years, acute PID (endometriosis, salpingitis, pyos-
alpinx, adnexitis, pelvic peritonitis, tubo-ovarian abscess). Diagnosis by manual exami-
nation, echography, laparoscopy, and clinical parameters such as fever, leukocytosis, ESR,
and positive bacterial culturing (anaerobe, aerobe, chlamydia).
Exclusion criteria: aged < 18 years; pregnancy or lactation; antibiotic therapy up to 3
days before inclusion; known allergies against gyrase-inhibitors, cephalosporine, metron-
idazole, and tetracycline; serious impaired renal and liver function; and other serious
comorbidities
Number of women randomized: 60.
Number of women analyzed: 57; group A: 26; group B: 31.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 3 women
excluded from analysis due to adverse effects
Number of centres: not stated.
Age (average (range)) (years): group A: 27 (30 ± 10); group B: 22 (26 ± 7).
Country: Germany.
Interventions Group A: ciprofloxacin 2 × 0.2 g IV daily + metronidazole 3 × 0.5 g IV daily
Group B: cefoxitin 3 × 2 g IV daily + doxycycline 2 × 0.1 g IV daily
After 2-5 days of treatment, ciprofloxacin, metronidazole, and doxycycline given PO.
Both groups treated for 7-14 days
Outcomes Primary outcome: clinical cure defined as subjective lack of symptoms, improvement
upon gynaecological examination, normal leukocytes count, declining ESR, no fever,
and elimination of bacteria
Notes Ethical approval: not mentioned.
Informed consent: yes, women gave written informed consent.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 57/60 women were available for analysis.
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Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Giraud 1989
Methods Randomized controlled trial.
Participants Inclusion criteria: women with severe PID.
Exclusion criteria: pregnant or likely to be pregnant, allergic to penicillin or to
cephalosporines, receiving concomitant treatment with allopurinol, needing to receive a
different antibiotic during hospitalization, infectious mononucleosis
Number of women randomized: 152.
Number of women analyzed: group A: 70; group B: 82.
Number of withdrawals/exclusions/loss to follow-up and reasons: 0.
Number of centres: unclear.
Age (mean) (years): group A: 26.9; group B: 25.1.
Country: France.
Interventions Group A: amoxicillin-clavulanic acid; while in hospital, 3 or 4 g per 24 h, by IV or
perfusion, then 2 or 3 g per 24 h PO
Group B: parenteral: ampicillin 3 or 4 g IV per 24 h, OR amoxicillin 3 g IV per 24 h +
gentamicin 160 mg IM per 24 h OR dibekacin 150 g IM per 24 h + metronidazole 1.5
g IV per 24 h. Oral administration: ampicillin 3 g per 24 h OR amoxicillin 2 g/24 h +
metronidazole 1.5 or 2 g per 24 h.
Additional treatments were limited, but could include: surgical or laparoscopic drainage
of pus, local antibiotic for treatment of trichomonacides, non-steroidal anti-inflamma-
tory drugs, corticoids
Outcomes Primary outcomes: clinical cure at 10th day; clinical progress and improvement of
biological parameters
Secondary outcome: length of hospital stay.
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated. No conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear how women were randomized.
Allocation concealment (selection bias) Unclear risk Not stated.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 20% attrition.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Heinonen 1989
Methods Randomized controlled trial.
Participants Women referred to Department of Obstetrics and Gynecology with suspected PID with
different degrees of severity (none, mild, moderate, and severe); 53% with mild degree
of salpingitis
Inclusion criteria: history of lower abdominal pain < 3 weeks’ duration, and presence
of cervical motion tenderness, uterine and adnexal tenderness on bimanual examination
Exclusion criteria: use of antibiotics, had any gynaecological operation or instrumenta-
tion of the upper genital tract in the preceding month, had systemic disease or epilepsy,
pregnant, suspected allergy to any of the drugs used, or puerperal infection
Number of women randomized: 40.
Number of women analyzed: group A: 16; group B: 20.
Number of withdrawal/exclusions/loss to follow-up and reasons: 4 due to other
diagnosis: toxoplasmosis, urinary infection, periappendicular abscess, no pathological
findings
Number of centres: 1.
Age (mean ± SD (range)) (years): group A: 29 ± 8 (18-43); group B: 29 ± 1 (16-50).
Country: Finland.
Interventions Group A: ciprofloxacin 200 mg IV every 12 h for 2 days followed by 750 mg PO every
12 h to complete 14-day course
Group B: doxycycline 100 mg IV every 12 h + metronidazole 500 mg IV every 8 h for
the first 2 days, followed by doxycycline 150 mg PO every 24 h + metronidazole 400
mg PO every 8 h to complete a 14-day course
Outcomes Primary outcomes: clinical response based on a scale from 0 (absent or normal) to 3+
(severe) assessed on days 3, 6, 14, and 21 after the antimicrobial treatment was started.
Failure defined as the presence of ≥ 1 of following criteria: no improvement in the
clinical severity score at day 3 after the microbial treatment was started; CRP > 20 mg/
L or a decline < 50% in the initial CRP level at day 6; positive cervical culture of N
gonorrhoeae or C trachomatis at days 14 or 21; or the need for additional antimicrobial
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agents or surgical intervention
Secondary outcomes: adverse reactions and effects.
Notes Ethical approval: not stated.
Informed consent: signed consent obtained.
Source of funding: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated how randomization was done.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated if all women were assessed 21 days after the
antimicrobial treatment was started
Hemsell 1994
Methods Randomized controlled trial.
Participants Inclusion criteria: clinical diagnosis of acute PID hospitalized at 1 of 6 sites for treat-
ment. Acute PID diagnosed in women with lower abdominal and pelvic pain and lower
abdominal and cervical motion and adnexal tenderness in addition to ≥ 1 of the fol-
lowing: oral temperature ≥ 38.0 °C; leukocyte count ≥ 10,500/mm3 ; elevated ESR;
endocervical specimen positive for Gram-negative intracellular diplococci; endocervical
or endometrial culture positive for N gonorrhoeae or C trachomatis; ultrasound findings
consistent with an adnexal inflammatory mass; or purulence in or a positive culture of
intraperitoneal material obtained at either culdocentesis or optional laparoscopy
Exclusion criteria: ruptured tubo-ovarian or pelvic abscess; history of hypersensitivity to
penicillin, cephalosporins, clindamycin, aminoglycosides, or tetracycline; among women
with IUD in place, those who permitted the removal of the device within 48 h were
included and those who did not were excluded; pregnancy or lactation; renal impairment
(a serumcreatinine level about 2mg/dL), neutropenia (< 1000 neutrophils/mm3 ), receipt
65Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hemsell 1994 (Continued)
of another investigational drug or another antibiotic up to 2 weeks before the time of
anticipated enrolment; and known or suspected active bacterial infection other than
acute PID that might subsequently require concomitant therapy
Number of women randomized: 344.
Number of women analyzed: group A: 109; group B: 110; group C: 108.
Number of withdrawal/exclusions/loss to follow-up and reasons: 52 women (15%)
were not evaluable, 21 enrolled incorrectly (i.e. despite a violation of inclusion or exclu-
sion criteria, or both), aII given an incorrect first dose of study drug or were subsequently
given incorrect doses, 10 left hospital against medical advice, 5 treated for < 48 h, 2
withdrew, 2 had adverse reactions resulting in the cessation of treatment, and 1 given
penicillin for the treatment of syphilis. Of the 2 women with adverse reactions, 1 devel-
oped blisters on her lips after the third dose of cefotetan + doxycycline, and the other
developed hives after the initial dose of cefoxitin. All 5 women who were not evaluable
because they received < 48 h of therapy had ≥ 1 abscesses, and 3/5 women underwent
surgery because of worsening symptoms. 2/5 women were in group A, 2 were in group
B, and 1 was in group 3. 20 of the unevaluable women were in group A, 20 were in
group B, and 12 were in group C
Number of centres: 6.
Age (mean ± SD) (years): success group: 24.7 ± 4.9; failure group: 26.2 ± 5.7.
Country: US.
Interventions Group A: cefoxitin 2 g IV every 6 h + doxycycline 100 mg every 12 h; followed by
doxycycline 100 mg PO twice daily for a total of 10-14 days
Group B: clindamycin 900 mg IV + gentamicin 1.5 mg/kg every 8 h after an initial
gentamicin loading dose calculated at 2 mg/kg followed by clindamycin 450 mg PO 4
times daily for a total of 10-14 days
Group C: cefotetan 2 g IV + doxycycline 100 mg every 12 h, followed by doxycycline
100 mg PO twice daily for a total of 10-14 days
Outcomes Primary outcome: clinical cure defined as reduction of the severity score by ≥ 70%,
with a normal temperature and leukocyte count
Secondary outcome: none reported.
Notes Ethical approval: consent forms were approved by the local institutional review board
at each centre
Informed consent: women aged 16-18 years old had to have parental consent, and
women aged ≥19 years had to give their own consent
Source of funding: ICI Pharmaceuticals Group (now ZENECA, Inc.), Wilmington,
Delaware. No conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not describedhow randomization codeswere generated.
Allocation concealment (selection bias) Unclear risk Not stated.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 292/343 women were analyzed (15% were not evalu-
able).
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Heystek 2009
Methods Randomized controlled trial.
Participants Inclusion criteria: women aged ≥ 18 years and receiving either hospital or outpatient
care for uncomplicated acute PID and using a reliable form of contraception
Exclusion criteria: positive serological test for syphilis or evidence of a pelvic abscess on
sonographic or laparoscopic examination
Number of women randomized: 686.
Number of women analyzed: 669; group A: 343; group B: 326.
Number of withdrawals/exclusions/loss to follow-up and reasons: 17; 2 never ran-
domized and in 15 it was impossible to confirm if they received study medication
Number of centres: 43.
Age (mean ± SD) (years): group A: 29.0 ± 7.3; group B: 28.2 ± 7.2.
Country: 14 countries.
Interventions Group A: moxifloxacin 400 mg PO once daily for 14 days.
Group B: doxycycline 100 mg PO twice daily + metronidazole 400 mg PO 3 times daily
for 14 days + ciprofloxacin 500 mg PO once
Outcomes Primary outcome (modified ITT): clinical cure at 2-14 days’ post treatment: clinical
success defined as cure (severity score reduced by ≥70%plus normal temperature and
leukocyte count) or improvement (severity score reduced <70% but >30% plus normal
temperature and leukocyte count). Therapy considered to have failed if symptoms and
signs of infection persisted or worsened, as shown by persistent fever, leukocytosis, a
reduction in severity score of ≤30%, or a combination of these. Clinical efficacy was
’unevaluable’ when a woman could not be assessed
Secondary outcome (PP): microbiological clearance of chlamydia, microbiological
clearance of gonorrhoea
Notes Ethical approval: yes, study protocol prepared in accordance with the European Guide-
lines for Good Clinical Practice (1991) and National Rules and Regulations. Study con-
ducted in accordance with the Declaration of Helsinki
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Informed consent: not stated.
Source of funding: Bayer Schering Pharma, Germany, provided financial and logistical
support. No conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate (< 20%).
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Hoyme 1993
Methods Randomized controlled trial.
Participants Inclusion criteria: women with laparoscopically verified salpingitis.
Exclusion criteria: none stated.
Number of women randomized: 33.
Number of women analyzed: 33; group A: 15; group B: 18.
Number of withdrawals/exclusions/loss to follow-up and reasons: 0.
Number of centres: 1.
Age (years): not stated.
Country: Germany.
Interventions Group 1: ofloxacin 2 × 200 mg + metronidazole 2 × 500 mg, first IV and then PO for
10 days in total
Group 2: gentamicin 3 × 80 mg + clindamycin 4 × 600 mg (initially 1200 mg IV) for
10 days in total
Outcomes Primary outcome: clinical cure, no raw data reported for outcomes.
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Notes Ethical approval: judged by the ethics committee.
Informed consent: yes, women gave written informed consent.
Source of funding: not stated, and no conflicts of interest reported.
All women hospitalized for the whole treatment.
Only percentages and no numbers reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Judlin 2010a
Methods Prospective, randomized, double-blind, double-dummy, parallel-group study
Participants No significant differences between treatment groups in demographic characteristics
Inclusion criteria: diagnosis of uncomplicated PID based on presence of all following
symptoms and signs: pelvic discomfort; direct lower abdominal tenderness; adnexal and
cervical motion tenderness on bimanual vaginal examination; and ≥ 1 of the following
signs: pyrexia (rectal, tympanic, or oral temperature > 38 °C or axillary temperature >
37.5 °C), CRP > 6 mg/L, WBC > 10,500/mm3 , laparoscopic evidence of PID, cervical
infection including mucopurulent cervical discharge or positive stain for Gram-negative
intracellular diplococci from the endocervix, and untreated, recent (< 14 days) docu-
mented gonococcal or chlamydial cervicitis
Exclusion criteria: pregnant or lactating; complicated PID (pelvic or tubo-ovarian ab-
scess ruled out by pelvic ultrasonography or laparoscopic examination within 48 h before
or 24 h after the start of therapy) or any condition likely to require surgical intervention
within 24 h of the start of treatment (or both); hypersensitivity to any study drug, re-
lated compound, or excipient; a history of tendon disorders associated with quinolones;
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history of clinically relevant cardiovascular abnormalities; history of epilepsy; defect in
glucose-6-phosphate dehydrogenase; receipt of systemic antibacterial therapy ≤ 7 days
before enrolment; history of uterine or pelvic or abdominal surgery ≤ 30 days before
treatment; intolerance to or inability to follow an oral antibiotic regimen; impaired liver
function (Child-Pugh C) or transaminase levels > 5 times the upper limit of normal (or
both); impaired renal function (creatinine clearance ≤ 50 mL/minute); neutropenia (<
1000/mm3); infection with HIV and CD4 count < 200/mm3; AIDS; and active an-
tiretroviral therapy.
Number of women randomized: 460.
Number of women analyzed: ITT: group A: 228; group B: 232; PP: group A: 194;
group B: 190
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 34 (vio-
lations of inclusion/exclusion criteria (n = 11); not treated with study drug (n = 3), non-
compliance with study drug (n = 4), insufficient duration of therapy (n = 9), violation
of time schedule (n = 5), informed consent withdrawn (n = 2), essential data missing/
invalid (n = 14), lost to follow-up (n = 2), use of prohibited concomitant medication (n
= 4); group B: 42 (violations of inclusion/exclusion criteria (n = 16); not treated with
study drug (n = 2), non-compliance with study drug (n = 2), insufficient duration of
therapy (n = 9), violation of time schedule (n = 6), informed consent withdrawn (n =
2), essential data missing/invalid (n = 18), lost to follow-up (n = 2), use of prohibited
concomitant medication (n = 6)
Number of centres: 7.
Age (mean ± SD) (years): group A: 35.2 ± 8.4; group B: 35.4 ± 8.7.
Countries:China, Indonesia, South Korea, The Philippines, Pakistan, Thailand, Taiwan
Interventions Group A: moxifloxacin 400 mg PO once daily for 14 days.
Group B: levofloxacin 500 mg (2 x 250 mg tablets) PO once daily + metronidazole 500
mg (1 tablet) PO twice daily for 14 days
Outcomes Efficacy: primary efficacy variable was clinical response at test-of-cure in the PP popula-
tion:
• ’Clinical success’ defined as women with clinical cure at test-of-cure; failures were
women with failure at the ’during therapy’ visit or improvement or failure at test-of-
cure.
• ’Clinical cure’ defined as reduction in tenderness score (McCormack scale) of >
70%, apyrexia (rectal/tympanic/oral temperature < 38.0 °C or axillary temperature <
37.5 °C) and WBC < 10,500/mm3 .
• ’Clinical improvement’ defined as reduction in tenderness score of 30-70%,
apyrexia (rectal/tympanic/oral temperature < 38.0 °C or axillary temperature < 37.5
°C) and WBC < 10,500/mm3 .
• ’Clinical failure’ defined as reduction in tenderness score of < 30% or elevated
temperature (rectal/tympanic/oral temperature ≥ 38.0 °C or axillary temperature < 37.
5 °C) or WBC ≥ 10,500/mm3 , or a combination of these.
Secondary efficacy variables:
• Clinical response during therapy (PP population) classified as ‘clinical
improvement’, defined as reduction in tenderness score of > 30% with improvement in
temperature, or ’clinical failure’, defined as persistence or worsening of symptoms and
signs of infection, as evidenced by a reduction in tenderness score of > 30% or no
improvement in temperature (or both).
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• Clinical response at follow-up (PP population) classified as ’continued cure’,
defined as reduction in tenderness score of > 70% compared with baseline and apyrexia,
or ’clinical relapse’, defined as reappearance of the signs and symptoms of PID.
• Clinical response at test-of-cure (microbiologically valid population) classified as
clinical cure, improvement, or failure, as defined for the primary efficacy variable.
• Bacteriological response at test-of-cure and follow-up (microbiologically valid
population) classified as ‘bacteriological success’, defined as eradication or presumed
eradication without occurrence of a superinfection, or ’bacteriological failure’, defined
as persistence, presumed persistence, or superinfection at test-of-cure, recurrence and
reinfection at follow-up, need to modify antibiotic therapy before test-of-cure, or need
to institute antibiotic therapy (for recurrence) between test-of-cure and end of follow-
up.
Safety: occurrence of adverse events (ITT population), including most commonly oc-
curring drug-related treatment-emergent events seen in > 2% of either group (ITT/
safety population). Safety evaluations included a physical examination (including vital
signs) at enrolment, during treatment, at the test-of-cure visit and at follow-up. Clinical
laboratory assessments (for blood chemistry and haematological parameters) performed
on blood samples taken within 48 h of the first dose of the study drug, and repeated at
test-of-cure and follow-up (in case abnormalities arose on or after the test-of-cure visit)
Notes Study funded by Bayer HealthCare AG, Leverkusen, Germany. 1 author (PJ) received
travel grants and consulting fees from GlaxoSmithKline and Sanofi-Pasteur-MSD, and
consulting fees from Bayer HealthCare. 2 authors (QL and ZL) declared no conflicts of
interest. 1 author (PR) was an employee of Bayer Vital GmbH; 2 authors (PA and BH)
were employees of Bayer Schering Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random code pro-
vided by Bayer Biometry (Wuppertal, Ger-
many); numbers assigned in sequential as-
cending order; no numbers left out or sub-
stituted
Allocation concealment (selection bias) Low risk Provided by the investigator in sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel administering
and assessing the outcome blinded to the
treatment given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and personnel administering
and assessing the outcome blinded to the
treatment given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate (< 20%).
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Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Low risk No other source of potential bias found for
ITT analysis.
Landers 1991
Methods Randomized controlled trial.
Participants Inclusion criteria: women with either laparoscopically confirmed salpingitis or histo-
logically confirmed plasma cell endometritis or they met previously published criteria
for non-invasive diagnosis of salpingitis. Criteria included direct abdominal tenderness,
cervical motion tenderness, and adnexal tenderness, plus ≥ 1 of the following: temper-
ature ≥ 38 °C, peripheral blood leukocytosis WBC > 10,500/mm3 , purulent material
or culdocentesis, evidence of pelvic abscess on ultrasonography or pelvic examination,
evidence of gonococcal or chlamydial cervicitis (by positive monoclonal antibody test
or by Gram’s stain showing gram-negative intracellular diplococcic), or mucopurulent
cervicitis as previously defined
Exclusion criteria: allergy to any of the 4 antibiotics involved in trial; pregnancy; or
history of pelvic surgery, abortion, uterine curettage, or delivery within 6 weeks of
admission
Number of women randomized: 162.
Number of women analyzed: 148, group A: 75; group B: 73.
Number of withdrawals/exclusions/loss to follow-up and reasons: 14; reasons for
exclusion: incorrect diagnosis that was discovered at laparoscopy or laparotomy, refusal
of the woman to remain hospitalized long enough to complete treatment
Number of centres: 2.
Age (mean ± SD) (years): total: 23.5 ± 6.1; group A: 23.3 ± 5.3; group B: 23.8 ± 6.0
Country: US.
Interventions Group A: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h for minimum
4 days and at least 48 h after disappearance of fever.Women without fever on admission
treated for minimum of 4 days in the hospital for at least 24 h beyond the adequate relief
of pain and tenderness to a normal lifestyle without surgical intervention. After discharge
from the hospital, doxycycline 100 mg PO twice daily was continued to complete a total
of 14 days of treatment
Group B: clindamycin 600 mg IV every 6 h + tobramycin 2 mg/kg IV for 1 dose,
followed by 1.5 mg/kg IV every 8 h for minimum of 4 days and for at least 48 h after
disappearance of fever. Women without fever on admission treated for minimum of 4
days in hospital for at least 24 h beyond adequate relief of pain and tenderness to a normal
lifestyle without surgical intervention. After discharge from hospital, clindamycin 450
mg PO 4 times daily continued to complete a total of 14 days of treatment
Outcomes Primary outcome (ITT): clinical response for a satisfactory initial clinical response
defined as an improvement of admitting signs and symptoms, included abdominal-pelvic
pain, fever, and pelvic tenderness. Follow-up evaluation performed at hospital discharge
and at 2-6 weeks after initial enrolment
Secondary outcomes (PP):microbiological clearance of C trachomatis and reduction in
72Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Landers 1991 (Continued)
tenderness score.
Notes Ethical approval: yes, study reviewed and approved by institutional review board at
both hospitals
Informed consent: yes, written informed consent obtained from all women before
enrolment
Source of funding: supported in part by National Institutes of Health grants AI12192
and 1PO1 AI24768 and by Merck, Sharp & Dohme, Westpoint, PA. No conflicts of
interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% follow-up.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Leboeuf 1987
Methods Randomized controlled trial.
Participants Inclusion criteria: women aged ≥ 18 years hospitalized with 1 of the following condi-
tions: endometritis, myometritis, postoperative infections in pelvic region, pelvic peri-
tonitis, acute adnexal infections such as salpingitis or pyosalpinx.
Exclusion criteria: allergy to clindamycin, lincomycin, metronidazole, or gentamicin;
colitis when taking antibiotics; taken antibiotics in the 48 h before entering study; preg-
nant or lactating; vestibular or cochlear lesion; renal insufficiency (creatinine > 12 mg/
L; WBC < 2000/mm2 ; platelets < 100,000/mm3 ; history of thrombopathy; peripheral
neuropathy; participation in another clinical trial
Number of women randomized: 45; group A: 23; group B: 22.
Number of women analyzed: 39; group A: 21; group B: 18.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 2; group
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B: 4. All unexplained.
Number of centres: 2.
Age (mean ± SD) (years): group A: 27.9 ± 5.2; group B: 29.1 ± 9.5.
Country: France.
Interventions GroupA: clindamycin 900mg IV every 8 h diluted in 150mL (minimumvolume) saline
slow perfusion (30-60 minutes) + gentamicin 1 mg/kg IM every 8 h (with minimum
dose prescribed of 60 mg every 8 h, according to bodyweight). Treatment given for
minimum of 5 days in hospital. Clindamycin perfusion not stopped until 48 consecutive
h with temperature below 37.5 °C; at that point treatment could be PO. Maximum
length of treatment at the discretion of the therapist. If also treated with a tetracycline,
this was not prescribed < 48 h after the end of the treatment protocol (either clindamycin
+ gentamicin or metronidazole + gentamicin)
Group B: metronidazole 500 mg every 8 h in slow IV perfusion (30-60 minutes) +
gentamicin 1 mg/kg IM every 8 h (with minimum dose prescribed of 60 mg every 8 h,
according to bodyweight). Treatment given for 6 weeks
Outcomes Primary outcome: clinical cure: absence of infection in the days following cessation of
treatment according to clinical observations,microbe eradicated during or after treatment
Secondary outcome: length of hospital stay.
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Mean days of hospitalization: 11.17 days.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition < 20%.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
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Methods Randomized controlled trial.
Participants Inclusion criteria: women with first episode of PID.
Exclusion criteria: women with recurrent PID or with previous antibiotic therapy
Number of women randomized: 165.
Number of women analyzed: 153 women; group A: 52; group B: 48; group C: 53.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 3 women
excluded from analysis; group B: 7; group C: 2
Number of centres: 1.
Age (mean ±SD) (years): group A without women excluded from analysis: 25.6 ± 3.9;
group B without women excluded from analysis: 25.8 ± 3.2; group C without women
excluded from analysis: 25.5 ± 4.9
Country: India.
Interventions GroupA: ciprofloxacin 500mg+ tinidazole 600mg (Table Brakke, Franko India Pharma,
Mumbai, India) twice daily for 7 days
Group B: fluconazole 150 mg (1 tablet) + azithromycin 1 g (1 tablet) + secnidazole 2
g (2 tablets) (Fas-3 kit Lyka, Mumbai, India). Advised to take azithromycin on empty
stomach in the morning, secnidazole with or after food and fluconazole in the evening
Group C: doxycycline 100 mg twice daily + metronidazole 200 mg 3 times daily for 1
week. The 2 drugs were available in the hospital pharmacy free of cost
Outcomes Primary outcome: clinical cure: women assessed at the first visit by a severity score
(Modified Severity Score of Soper 1988) the findings at the first examination and severity
score noted in the Performa filled for every woman. The women were asked to report
after 1 week and 4 weeks. Repeat gynaecological examination and severity score were
performed and recorded in the Performa. All women were advised to report within 3
days if there was no improvement in symptoms, any deterioration in their condition,
or inability to carry on with the oral therapy when they were hospitalized. Clinical cure
defined as at least 70% reduction in severity score, no more than mild abdominal pain,
and no recurrence of symptoms or signs of PID within 4 weeks of therapy. Treatment
failure defined as < 20% decrease in tenderness score
Modified ITT (cases that were not PID were excluded).
Group A: 52.
Group B: 48.
Group C: 53.
Notes Ethical approval: yes, the departmental ethical committee approved the study.
Informed consent: yes, verbal informed consent taken from all the women.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a computer-generated number, all women were
randomized to 1 of 3 treatment groups initially, and later
it was a block randomization to equalize the group
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Allocation concealment (selection bias) Unclear risk Not reported by whom allocation was done and how.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Unfortunately we could not get similar looking packs
from the market so the assignment was not concealed
from the investigator.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Unfortunately we could not get similar looking packs
from the market so the assignment was not concealed
from the investigator.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12/165 women excluded from analysis.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Maria 1992
Methods Randomized controlled trial.
Participants Inclusion criteria: women aged 15-51 years who required hospitalization for treatment
of acute PID based on clinical and laboratory evidence. All women had abdominal,
parametrial, and cervicalmotion tenderness. The additional finding of fever, leukocytosis,
pelvic mass, or purulent material in the peritoneal cavity confirmed the diagnosis
Exclusion criteria: allergies to study drugs, requirement for concomitant therapy with
other antibiotics, and > 2 doses of antibiotics in the 7 days prior to admission
Number of women randomized: 170 women; group A: 88; group B: 82.
Number of women analyzed: 170 women; group A: 88; group B: 82.
Number of withdrawals/exclusions/loss to follow-up and reasons: groupA: 28; group
B: 27 due to failure to follow randomization scheme, protocol deviation, and incorrect
diagnoses
Number of centres: 10.
Age (mean) (years): whole study group: 28; age per group not stated.
Country: 9 in Europe and 1 Africa.
Interventions Group A: clindamycin 900 mg IV every 8 h + gentamicin 2 mg/kg IV, followed by 1.
5 mg/kg IV every 8 h for minimum of 4 days. At the end of the period of IV therapy,
clindamycin 450 mg PO every 6 h was given to complete 14 days of treatment
Group B: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h were given for
at least 4 days. At the end of IV therapy, doxycycline 100 mg PO was given every 12 h
to complete a total of 14 days of treatment
Outcomes Primary outcomes: clinical failure, minimum of 48 h of protocol therapy and charac-
terized by signs and symptoms as unchanged or worsened during the first 48-72 h of
treatment, or worsening later, failure to improve further; need of additional antibiotics
or need for surgery considered as failure; adverse events leading to discontinuation of
therapy
76Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Maria 1992 (Continued)
Secondary outcomes: microbial cure of C trachomatis and N gonorrhoeae.
Notes Ethical approval: not stated.
Informed consent: yes, informed consent obtained from all women prior to entry into
the trial
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated how randomization sequence was generated.
Allocation concealment (selection bias) Unclear risk Not stated by whom allocation concealment was done.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study.
Incomplete outcome data (attrition bias)
All outcomes
High risk 115/170 women analyzed (68%).
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Martens 1990
Methods Randomized controlled trial.
Participants Inclusion criteria: diagnosis of PID based upon the following signs and symptoms: oral
body temperature≥ 38.3 °C, lower abdominal tenderness, cervical or uterine tenderness
on palpation and motion, and tenderness on palpation of adnexa. In addition, the
following may have been present: purulent endocervical discharge, WBC≥ 14,000/mm
3, adnexal mass or abscess, nausea, and vomiting. Women selected for the uncomplicated
PID group if the above criteria were met, but no adnexal mass was noted on palpation,
ultrasonography, or at the time of surgery. In the complicated PID group, women with
tubo-ovarian complex did not meet the above criteria and had evidence of a unilateral
or bilateral adnexal mass on pelvic examination, not confirmed by a radiolucent area
on ultrasound examination or surgery. Women with tubo-ovarian abscess had the above
findings including a radiolucent area on ultrasound, consistent with an abscess or pus-
filled cavity noted at surgery
Exclusion criteria: not stated.
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Number of women randomized: 99.
Number of women analyzed: 94.
Number of withdrawals/exclusions/loss to follow-up and reasons: 5 women were
excluded from evaluation due to protocol violations
Number of centres: not stated.
Age (mean ± SD) (years): group A: 26 ± 7; group B: 25 ± 7; group C: 26 ± 7.
Country: not stated.
Interventions Group A: cefoxitin 2 g every 6 h for minimum of 4 days and continued until the woman
was apyrexial with improvement of symptoms for at least 48 h
Group B: cefotaxime 2 g every 8 h for minimum of 4 days and continued until the
woman was apyrexial with improvement of symptoms for at least 48 h
Group C: clindamycin 900 mg every 8 h + gentamicin at initial loading dose of 120
mg, followed by maintenance doses of 80 mg every 8 h. Subsequent maintenance doses
determined by evaluating trough and peak serum aminoglycoside concentrations. An-
tibiotics given for minimum of 4 days, and continued until the woman was apyrexial
with improvement of symptoms for at least 48 h
Outcomes Primary outcome: clinical failure: evaluated on a daily basis. Women who had not
demonstrated signs of improvement after 48-72 h of antibiotic therapy were considered
an unsuccessful result
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest declared.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk There were 2 randomization codes, 1 for each diagnosis
group
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94/99 women included in the analysis.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
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Methods Randomized controlled trial.
Participants Inclusion criteria: non-pregnant, non-lactating women using a reliable form of con-
traception and who fulfilled the diagnostic criteria for uncomplicated PID. Diagnostic
inclusion criteria for uncomplicated PID were all the following: direct lower abdominal
tenderness with or without rebound tenderness, cervical motion tenderness, and adnexal
tenderness. Plus ≥ 1 of the following: recent positive endocervical culture for N gonor-
rhoeae or C trachomatis, temperature > 38 °C), WBC count > 10,000/mm3 , leukocytic
endocervical discharge.
Exclusion criteria: pelvic infection severe enough to require parenteral antimicrobial
therapy or if surgical intervention within the next 24 h was anticipated; evidence of a
pelvic abscess by ultrasonography or clinical examination; if pain had been present for >
2 weeks; allergy to study medications; major gastrointestinal, renal, or hepatic disorders;
used other antimicrobial agents within the previous 2 weeks; IUD in place; or alcohol
or drug abusers
Number of women randomized: total: 295; group A: 150; group B: 145.
Number of women analyzed: total: 249; group A: 128; group B: 121.
Number of withdrawals/exclusions/loss to follow-up and reasons: 46 women ex-
cluded from analysis due to protocol violations or loss to follow-up
Number of centres: 16.
Age (mean ± SD) (years): group A: 25.9 ± 5.8; group B: 26.0 ± 6.8.
Country: US.
Interventions Group A: ofloxacin 400 mg PO every 12 h for 10 days.
Group B: cefoxitin 2 g IM + probenecid 1 g PO, followed by doxycycline 100 mg PO
every 12 h for 10 days
Outcomes Primary outcomes: clinical cure: complete resolution of tenderness; clinical improve-
ment: partial resolution of tenderness without the need for additional antibiotic therapy
Secondary outcomes:microbial cure of C trachomatis, microbial cure of N gonorrhoeae.
Notes Ethical approval: yes, “with approval from their respective institutional review boards.”
Informed consent: yes, “the subjects were enrolled after giving informed consent.”
Source of funding: supported in part by a grant from Ortho Pharmaceutical Corpora-
tion, Raritan, New Jersey. No conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk After obtaining informed consent, women given a com-
puter-generated randomization code number and as-
signed to either treatment regimen using 1:1 ratio
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 46/295 women excluded from analysis due to protocol
violations or loss to follow-up (< 20%)
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Okada 1988
Methods Randomized controlled trial.
Participants Inclusion criteria: women aged ≥ 16 years, inpatients and outpatients; intrauterine
infection, uterine adnexitis, bartholinitis, or bartholin’s abscess
Exclusion criteria: age < 16 years; premedication with ciprofloxacin or cefroxadine;
women improving with other treatments; allergy to cephem or pyridonecarboxylic acid;
taking theophylline or fenbufen, severe problems in the heart, liver, or kidneys; women
with epilepsy; pregnant or breastfeeding; rejection by the doctor
Number of women randomized: total: 253; group A: 124; group B: 129.
Number of women analyzed: total: 209; group A: 104; group B: 105.
Number of withdrawals/exclusions/loss to follow-up and reasons: total: 44; group
A: 20; group B: 24. No reasons presented.
Number of centres: 55.
Age (years): only presented as frequencies within age groups.
Country: Japan.
Interventions Group A: ciprofloxacin 200 mg PO + dummy cefroxadine placebo, 3 times daily for 7
consecutive days
Group B: cefroxadine 250 mg PO + dummy ciprofloxacin placebo, 3 times daily for 7
consecutive days
Outcomes Primary outcomes: clinical cure at 7th day of treatment: excellent: clinical marked
improvement and clearance of bacteria; good: clear clinical improvement; poor: no clear
clinical improvement; adverse events
Secondary outcome: local tenderness around uterus.
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk 2 ciprofloxacin and 2 cefroxadine each with dummy
placebo were arranged for 7-day-use and numbered.
Numbers randomly assigned. 4 series of numbered
medicine packed in a box. Then, some boxes were de-
livered to every institution
Allocation concealment (selection bias) Unclear risk Having used numbered series of medicine to women
consecutively
Block size of 4 and might be too small for concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy placebo method.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind method.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition < 20%.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Ross 2006
Methods Randomized controlled trial.
Participants Inclusion criteria: women with uncomplicated PID, confirmed by absence of pelvic or
tubo-ovarian abscess on transabdominal/transvaginal pelvic ultrasound or laparoscopy
(within 2 days before or 1 day after the start of treatment), or both ultrasound and
laparoscopy. Diagnosis of PID was based on the presence of all the following: pelvic
discomfort, direct lower abdominal tenderness with or without rebound tenderness, and
adnexal/cervical motion tenderness on bimanual vaginal examination. In addition, ≥ 1
of the following signs: raised temperature (> 37.5 °C); ESR > 15 mm in the first hour;
CRP value above the upper limit of the normal range; WBC count > 10,500/mm3 ;
laparoscopic evidence of PID; signs suggestive of cervical infection (e.g. mucopurulent
cervical discharge); or untreated, documented gonococcal or chlamydial cervicitis within
the previous 14 days
Exclusion criteria: contraindications to study drugs; required surgery within the next
24 h or had a history of uterine or pelvic or abdominal surgery within the past 30 days;
or previous treatment with systemic antibiotic therapy in the last 7 days
Number of women randomized: 749.
Number of women analyzed: group A: 384; group B: 365.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 51 (24
due to adverse events; 14 consent withdrawn; 7 lost to follow-up; 2 non-compliant; 1
protocol violation; 2 insufficient therapeutic effect; 1 investigator decision); group B: 38
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(17 due to adverse events; 9 consent withdrawn; 5 lost to follow-up; 4 non-compliant;
3 protocol violation)
Number of centres: 13.
Age (mean ± SD) (years): group A: 30.1 ± 8.4; group B: 30.5 ± 8.5.
Countries: Denmark; Finland; France; Germany; Greece; Hungary; Italy; Lithuania;
Poland; Russia; South Africa; Sweden; UK
Interventions Group A: moxifloxacin 400 mg PO once daily for 14 days.
Group B: ofloxacin 400 mg PO twice daily + metronidazole 500 mg PO twice daily for
14 days
Outcomes Primary outcome: clinical cure (5-24 days post-therapy): reduction of the pelvic pain
score by >70%(McCormack score, table A) + apyrexia (rectal/tympanic/oral temperature
< 38.0 °C or axillary/cutaneous temperature < 37.5 °C) + WBC count < 10,500/mm3 .
Secondary outcomes:microbial cure of C trachomatis; microbial cure of N gonorrhoeae.
Notes Ethical approval: study protocol prepared in accordance with the Declaration of
Helsinki and ethical approval obtained for each centre
Informed consent: written, informed consent obtained from each woman.
Source of funding: grant from Bayer HealthCare. No competing interests declared for
4 authors (HC, TP, IR, or DV). 1 author (JR) received payment as a consultant and
lecturer, and sponsorship to attendmedical conferences fromBayerHealthCare. 1 author
(JR) was an associate editor of Sexually Transmitted Infections. 4 authors (AK, MA, PA,
and PR) were employees of Bayer HealthCare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No description of how randomization was generated.
Author retrieved information from full report
Allocation concealment (selection bias) Low risk No description if allocation was concealed. After con-
sulting the full report, the author stated that allocation
was made by the pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding achieved by dispensing medication with iden-
tical packaging (blister packs) and appearance (all drugs
and placebo tablets were encapsulated)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition < 20%.
Selective reporting (reporting bias) Low risk Trial protocol was published in www.stijournal.com/
supplemental
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Other bias Unclear risk Not stated.
Roy 1985
Methods Randomized controlled trial.
Participants Inclusion criteria: not stated.
Exclusion criteria: not stated.
Number of women randomized: 46 (36 with acute PID).
Number of women analyzed: group A: 19; group B: 9; group C: 9.
Number of withdrawals/exclusions/loss to follow-up and reasons: all 46 women
completed the study; however, only 36 had acute PID
Number of centres: 1.
Age (years): not stated.
Country: US.
Interventions Group A: cefotaxime 2 g IV or IM every 8 h.
Group B: clindamycin 600 mg IV every 6 h + gentamicin 1.5 mg/kg lean bodyweight
IV or IM every 8 h
Group C: clindamycin 600 mg IV every 6 h + gentamicin 1.5 mg/kg lean bodyweight
IV or IM every 8 h + penicillin G 5 million units IM every 4 h
Outcomes Primary outcomes: clinical cure: antibiotic change was made for treatment failure from
an assigned regimen based upon persistence or worsening of signs and symptoms after
48 h
Secondary outcomes: none reported.
Notes Ethical approval: not stated.
Informed consent: yes, enrolled after informed consent obtained.
Source of funding: not stated, and no conflicts of interest reported.
Range of hospital stay: 3-11 days.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
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Roy 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized completed the study.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Roy 1990
Methods Randomized controlled trial.
Participants Inclusion criteria: lower abdominal pain and tenderness, cervical motion or adnexal
tenderness, and 1 of the following: oral temperature > 38 °C, leukocytosis > 10,500/mm
3, or presence of a suspected inflammatory pelvic mass on examination or by ultrasound
Exclusion criteria: allergy to cephalosporins or penicillins; had taken antibiotics in the
previous 3 days; had received any investigational drugs in the previous 30 days; pregnant
or breastfeeding; rapidly progressive underlying disease that could preclude evaluation
of therapy; or required other systemic antibiotics on admission
Number of women randomized: 67.
Number of women analyzed: total: 67; group A: 13; group B: 14; group C: 19; group
D: 21
Number of withdrawals/exclusions/loss to follow-up and reasons: 3 women, 1 be-
cause of protocol violation and 2 left the study before completion of therapy
Number of centres: 1.
Age (mean ± SEM) (years): group A: 26.6 ± 1.9; group B: 28.9 ± 1.7; group C: 27.1 ±
1.3; group D: 28.3 ± 1.0
Country: US.
Interventions Group A: ceftizoxime 2 g IV every 12 h + doxycycline 100 mg IV twice daily
Group B: ceftizoxime 2 g IV every 6 h + doxycycline 100 mg IV twice daily
Group C: ceftizoxime 2 g IV every 8 h + doxycycline 100 mg IV twice daily
GroupD: clindamycin 900mg IV every 8 h + gentamicin 2mg/kg loading dose followed
by 1.5 mg/kg IV every 8 h with adjustments if necessary
Outcomes Primary outcomes: clinical cure: adequate response to therapy: clinically improved and
afebrile for 48 h at the time of discharge; 8-24 before discharge; no pelvic tenderness;
adverse events leading to discontinuation of therapy
Secondary outcomes:microbial cure of C trachomatis, microbial cure of N gonorrhoeae,
and length of hospital stay.
Notes Ethical approval: not stated.
Informed consent: yes, women signed informed consent forms previously approved by
institutional review board
Source of funding: financial assistance, in part, provided by Smith Kline & French
Laboratories, Philadelphia, PA. No conflicts of interest reported
Follow-up: 10-14 days.
Risk of bias
84Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roy 1990 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3womenwithdrew from the study or were lost to follow-
up.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Savaris 2007
Methods Randomized controlled trial.
Participants Inclusion criteria: history of pelvic discomfort for < 30 days, with findings of pelvic
organ tenderness (uterine or adnexal) on bimanual examination, and leukorrhoea or
mucopurulent cervicitis
Exclusion criteria: current urinary infection; pregnancy; presence of tubo-ovarian ab-
scess, endometriosis, appendicitis, diverticulitis, haemorrhagic ovarian cysts or torsion;
abdominal hernia; homelessness; fever > 38 °C; abdominal rebound tenderness; pelvic
pain > 30 days’ duration; allergy to ceftriaxone, azithromycin, or doxycycline; history of
antimicrobial therapy within 7 days of recruitment; delivery, abortion, or gynaecological
surgery within 30 days; prior hysterectomy or bilateral salpingectomy; and oral intoler-
ance for the antibiotics.
Number of women randomized: 133.
Number of women analyzed: group A: 66; group B: 67.
Number of withdrawals/exclusions/loss to follow-up and reasons: group A: 4 lost
to follow-up, 2 discontinued intervention (1 oral intolerance, 1 worsening of the pain);
group B: 7 lost to follow-up: 9 discontinued intervention (2 oral intolerance, 7 worsening
of pain)
Number of centres: 1.
Age (mean ± SD) (years): group A: 28.3 ± 0.8; group B: 29.27 ± 1.1.
Country: Brazil.
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Interventions Group A: ceftriaxone IM 250 mg + azithromycin 1 g PO single dose and repeated after
7 days
Group B: ceftriaxone IM 250 mg + doxycycline 200 mg PO for 14 days.
Outcomes Primary outcome: clinical cure defined as≥ 70% reduction in the total tenderness score
at day 14 compared with baseline, for both visual analogue scale and McCormack pain
scale
Secondary outcome: microbial cure of C trachomatis.
Notes Ethical approval: study protocol approved by ethics committee of Hospital de Clínicas
de Porto Alegre, and registered at isrctn.org under ISRCTN46117662
Informed consent: enrolled in study after signing the informed consent.
Source of funding: supported by Grupo de Pesquisa e Pos-Graduacão Do Hospital de
Clínicas de Porto Alegre under grant # 03/006. GenProbe (San Diego, CA) donated the
kits to run the bacteriological analysis, and Pfizer (New York, NY) donated azithromycin
to the Global Program to Eliminate Trachoma (Dr Schachter had a National Institutes of
Health grant to do operational research on azithromycin treatment of trachoma, and the
company donated the drug). The drug used in this study was obtained independently in
Brazil, without Pfizer support. The other authors had no potential conflicts of interest
to disclose
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used computer-generated table for allocation sequence.
Women allocated in blocks of 4
Allocation concealment (selection bias) Low risk To avoid bias, bothmedicationsweremanipulated by the
hospital pharmacy and put in identically coded blisters
and capsules. Because of the difference in the number
of capsules in each treatment, the empty azithromycin
blisters were filled with placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women and assessors blinded to group assignment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Women and assessors blinded to group assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate (< 20%).
Selective reporting (reporting bias) Low risk Trial protocol published (ISRCTN46117662).
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Other bias Unclear risk The drug used in this study was obtained independently
in Brazil, without Pfizer support. Analysis was provided
asmodified ITT, where conditions others than PIDwere
excluded from analysis after randomization
Sirayapiwat 2002
Methods Randomized controlled trial.
Participants Inclusion criteria: aged > 16 years old; give written consent prior to entry; clinical
diagnosis of acute PIDmadewhenwomanhad all following: lower abdominal tenderness,
adnexal tenderness, and cervical motion tenderness;≥ 1 of following: oral temperature≥
38.3 °C, abnormal cervical discharge, elevated ESR or CRP, and endocervical specimen
positive for N gonorrhoeae or C trachomatis.
Exclusion criteria: pregnant or lactation; history of hypersensitivity to penicillin, amino-
glycoside, clindamycin, or metronidazole; severe hepatic disease; renal impairment
(serum creatinine level > 2 mg/dL), or evidence of ruptured tubo-ovarian abscess
Number of women randomized: 44; 22 in each group.
Number of women analyzed: 44; 22 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 0 reported as lost
to follow-up.
Number of centres: 1.
Age (mean ± SD) (years): group A: 31.2 ± 9.1; group B: 24.9 ± 7.6.
Country: Thailand.
Interventions Group A: (triple therapies) received intravenous therapy of 1 gm of ampicillin every
6 hours plus 5 mg/kg. (not exceed 240 mg) of gentamicin once daily and 500 mg of
Metronidazole every 8 hours
Group B: clindamycin 600 mg IV every 8 h + gentamicin 5 mg/kg not exceeding a
maximum dose of 240 mg once daily
In both groups, parenteral therapies continued until women were afebrile for minimum
of 48 h then all women received a regimen of doxycycline 100 mg PO every 12 h to
complete a 14-day course
Outcomes Primary outcomes: clinical cure; adverse events leading to discontinuation of therapy
Secondary outcome: length of hospital stay.
Visual analogue scale on day 3 of treatment.
Notes Ethical approval: yes, approval for study obtained from the Ethical Committee of the
Faculty of Medicine, Chulalongkorn University before trial was started
Informed consent: yes, all women gave written consent before entering into study
Source of funding: not stated, and no conflicts of interest reported.
There were significant baseline imbalances between the 2 groups. Age, infertility, and
severity of pain prior to this study significantly lower in group B (clindamycin/gentam-
icin)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization codes computer-generated and sealed in
envelope, then women were randomly assigned to 1 of
the 2 regimens depending on their codes (A or B)
Allocation concealment (selection bias) Unclear risk Not stated by whom allocation concealment was done.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Soper 1988
Methods Randomized controlled trial.
Participants Inclusion criteria: written informed consent; met criteria for diagnosis of PID with the
following: lower abdominal pain and bilateral adnexal tenderness on bimanual pelvic ex-
amination; microscopy of a wet mount of the vaginal contents revealing marked increase
in the number of leukocytes (i.e. leukocytes outnumbered all other cellular elements in
the smear); ≥ 2 of the following: temperature > 38 °C, leukocytosis (> 11,000/mm3)
, purulent material from the peritoneal cavity by culdocentesis, inflammatory complex
on bimanual examination or sonography, ESR > 20 mm/h; uncomplicated salpingitis
limited to tube(s) or ovary(ies) (or both) without pelvic peritonitis; complicated (inflam-
matory mass or abscess involving tube(s) or ovary(ies) (or both) with or without pelvic
peritonitis
Exclusion criteria: pregnant; history of allergy to 1 of study drugs.
Number of women randomized: 62; 31 in each group.
Number of women analyzed: 62; 31 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 0 reported as lost
to follow-up.
Number of centres: 1.
Age (mean ± SD) (years): group A: 23.4 ± 5.8; group B: 21.9 ± 3.7.
Country: US.
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Interventions Group A: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h. Women
discharged with doxycycline 100 mg PO twice daily to complete a 10-day course
Group B: clindamycin 600 mg IV every 6 h + amikacin 7.5 mg/kg IV every 12 h.
Women discharged with clindamycin 300 mg PO 4 times daily to complete a 10-day
course
Outcomes Primary outcome: clinical failure: persistence of fever (> 38 °C), elevated WBC (> 11,
000/mm3), moderate-severe pelvic organ tenderness despite 96 h of antibiotic therapy,
need of laparotomy
Secondary outcome: length of hospital stay.
Notes Ethical approval: not stated.
Informed consent: yes, enrolled after obtaining informed consent according to guide-
lines of the Human Research Committee
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Women admitted to hospital and assigned randomly in
a double-blind fashion, to 1 of 2 treatment regimens
by sealed envelope, generated from a table of random
numbers
Allocation concealment (selection bias) Unclear risk Allocation reported to have taken place in sealed en-
velopes, but it was not reported who distributed them
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated who was blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated who was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias High risk Significant baseline imbalances between the 2 groups.
Age, infertility, and severity of pain prior to this study
was significant lower in group B (clindamycin/gentam-
icin)
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Sweet 1985
Methods Randomized controlled trial.
Participants Inclusion criteria: none stated.
Exclusion criteria: none stated.
Number of women randomized: 60; 30 in each group.
Number of women analyzed: 60; 30 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 0 reported as lost
to follow-up.
Number of centres: 1.
Age (mean ± SD) (years): group A: 24.2 ± 5.1; group B: 24.7 ± 7.2.
Country: US.
Interventions Group A: moxalactam 2 g IV every 8 h.
Group B: clindamycin 600 mg IV every 6 h + tobramycin 1.5 mg/kg every 8 h
Outcomes Primary outcome: microbiological cure.
Secondary outcome: length of hospital stay.
Notes Ethical approval: not stated.
Informed consent: yes, all women gave informed consent approved by the University
of California (San Francisco) Committee on Human Research
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Women randomized using a computer-generated ran-
domized schedule
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomized were analyzed.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
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Thadepalli 1991
Methods Randomized controlled trial.
Participants Inclusion criteria: women of reproductive age who had clinical features of PID, acute
salpingitis, or suspected pelvic abscess, such as lower abdominal pain associated with
fever and chills, and cervical motion tenderness with or without signs of adnexal masses;
required hospitalization for IV antibiotic therapy. In all cases, CDC criteria for PID
satisfied
Exclusion criteria: suspected or known to be pregnant; breastfeeding.
Number of women randomized: 71; group A: 35; group B: 36.
Number of women analyzed: 61; group A: 31; group B: 30.
Number of withdrawals/exclusions/loss to follow-up and reasons: 10 women; group
A: 4; group B: 6 later excluded from evaluation due to wrong diagnosis or protocol
violations
Number of centres: not stated.
Age (mean (range)) (years): group A: 27.5 (15-37); group B: 26.5 (19-36).
Country: not stated.
Interventions Group A: ciprofloxacin 300 mg IV twice daily for ≥ 3 days followed by ciprofloxacin
500 mg PO twice daily for about 1 week
Group B: clindamycin 600 mg IV every 6 h + gentamicin 80 mg IV every 8 h, admin-
istered separately. Clindamycin by IV route for 3 days, followed by oral administration
for about 1 week. Gentamicin dose adjusted based on serum creatinine and gentamicin
levels
Outcomes Primary outcomes: clinical cure: when there was resolution or clearing (or both) of signs
of infection as evidenced by defervescence, reversal of leukocytosis, and abatement of
abdominal pain and cervicalmotion tenderness; adverse events leading todiscontinuation
of therapy
Secondary outcome: length of hospital stay.
Notes Ethical approval: study protocol approved by the Human Rights Committee of their
institution
Informed consent: yes, all women entered in study were informed in full and required
to read and sign a consent form
Source of funding: supported by Miles Laboratory, New Haven, CT, a subsidiary of
Bayer, Leverkusen, West Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer-generated randomization scheme.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
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Thadepalli 1991 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/71 women not analyzed (14%).
Selective reporting (reporting bias) Unclear risk No trial protocol found.
Other bias Unclear risk Not stated.
Tison 1988
Methods Randomized controlled trial.
Participants Inclusion criteria: upper genital tract infection, pelvic pain (bilateral, unilateral), fever
> 37.5 °C, leukorrhoea, bleeding, digestive and urinary signs, pain in right hypochon-
drium. Diagnosis confirmed by laparoscopy
Exclusion criteria: pregnant or likely to be; allergy to penicillin or cephalosporins;
receiving concomitant treatment with allopurinol; already received an antibiotic before
admission; renal insufficiency
Number of women randomized: 40; 20 in each group.
Number of women analyzed: 40; 20 in each group.
Number of withdrawals/exclusions/loss to follow-up and reasons: 1 woman with-
drawn during hospital admission; 13 women lost to follow-up
Number of centres: 1.
Age (mean (range)) (years): group A: 27.5 (17-39); group B: 22.5 (17-34).
Country: France.
Interventions Group A: amoxicillin-clavulanate 1 g slow IV perfusion every 8 h. PO once temperature
normal for 48 h, 4 tablets of 500 mg, 2 at a time as long as hospitalized. After discharge,
treatment continued with 3 tablets daily of amoxicillin-clavulanate for 3 weeks
GroupB:penicillinG10millionunits/24h IV, followedby penicillinVPO+gentamicin
160 mg/24 h IM for 10 days + metronidazole 500 mg IV 3 times daily followed by
metronidazole 500 mg PO 3 times daily
Duration of treatment unclear.
Outcomes Effectiveness: cure: absence of pelvic pain on examination and referred bywomen, normal
body temperature at discharge and 3 weeks later
Adverse events: any antibiotic-related adverse event leading to discontinuation of therapy
during hospital stay and after 30 days
Notes Ethical approval: not stated.
Informed consent: not stated.
Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
Other bias Unclear risk Not possible to identify.
Walters 1990
Methods Randomized controlled trial.
Participants Inclusion criteria: women hospitalized from July 1986 to December 1988 with clinical
diagnosis of acute PID diagnosed using the criteria proposed by Hager and colleagues
(Hager 1983), and candidates for therapy.
Exclusion criteria: aged < 15 years; pregnant; allergic to 1 of the study drugs or penicillin;
concomitant infection requiring another antibiotic; serum creatinine level > 1.5 mg/dL;
received any antibiotic therapy during the past 7 days; or pelvic or abdominal surgery in
the past 30 days
Number of women randomized: 147; unclear how many in each group.
Number of women analyzed: group A: 63; group B: 67. PP analysis only.
Number ofwithdrawals/exclusions/loss to follow-up and reasons:17women received
< 48 h of protocol therapy and were removed from the study. Of these exclusions,
diagnosis wasmade in error in 11women; 2 did notmeet the inclusion criteria; 2 required
emergency surgery for ruptured tubo-ovarian abscess within 24 h of admission and 2
left hospital against medical advice
Number of centres: 1.
Age (mean ± SD) (years): total age not stated; group A: 25.4 ± 7.7; group B: 24.5 ± 7.8
Country: US.
Interventions Group A: gentamicin 2.0 mg/kg IV as loading dose, then 1.5 mg/kg IV every 8 h +
clindamycin 900 mg IV every 8 h for minimum 4 days. After discharge, clindamycin
450 mg PO every 6 h for total 14 days
Group B: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h for minimum
93Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Walters 1990 (Continued)
4 days. After discharge, doxycycline 100 mg PO every 12 h for total 14 days
Outcomes Primary outcomes: clinical cure defined as oral temperature < 38 °C for 48 h, resolution
of pain and tenderness, and no increase in the size of any pelvic mass after 21 days of
initiation of treatment
Secondary outcomes:microbiological clearance of chlamydia;microbiological clearance
of gonorrhoea after 21 days of initiation of treatment
Notes Ethical approval: not stated.
Informed consent: informed consent obtained and approved by Institutional Review
Board of The University of Texas Health Science Center at San Antonio
Source of funding: supported by grant from the Upjohn Co., Kalamazoo, MI. No
conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated table.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 147 women randomized, 17 received < 48 h of pro-
tocol therapy and were removed from the study
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
Wendel 1991
Methods Randomized controlled trial.
Participants Inclusion criteria: non-pregnant, non-lactating women using a reliable form of contra-
ception who met the inclusion criteria for acute salpingitis
Exclusion criteria: pelvic infection severe enough to require parenteral antimicrobial
therapy (diffuse peritonitis) or if surgical intervention within the next 24 h was antici-
pated; evidence of a pelvic abscess on sonographic or clinical examination
Number of women randomized: 96; unclear how many to each group.
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Number of women analyzed: group A: 35; group B: 37. PP analysis only.
Number of withdrawals/exclusions/loss to follow-up and reasons: 24 women con-
sidered unevaluable because of total non-compliance with study drug (1 woman) or lack
of attendance at any follow-up visits (23 women)
Number of centres: 1.
Age (mean) (years): total age not stated; group A: 24.7; group B: 23.3.
Country: US.
Interventions Group A: cefoxitin 2 g IM + probenecid 1 g PO followed by doxycycline 100 mg PO
every 12 h for 10 days
Group B: ofloxacin 400 mg PO every 12 h for 10 days.
Outcomes Primary outcomes: clinical cure defined as complete resolution of tenderness (> 65%
decrease in clinical score); adverse events leading to discontinuation of therapy
Secondary outcomes:microbiological clearance of chlamydia;microbiological clearance
of gonorrhoea
Notes Ethical approval: unclear. Study approved by Texas Southwestern Medical Center In-
stitutional Review Board
Informed consent: women enrolled after they gave informed consent.
Source of funding: supported in part by a grant from Ortho Pharmaceutical Corpora-
tion, Raritan, NJ. No conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/96 women considered unevaluable.
Selective reporting (reporting bias) Unclear risk No study protocol found.
Other bias Unclear risk Not stated.
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CDC: Centers for Disease Control and Prevention; ESR: erythrocyte sedimentation rate; h: hour; IM: intramuscular; ITT: intention to
treat; IV: intravenous; n: number of women; PID: pelvic inflammatory disease; PO: per os; PP: per protocol; SD: standard deviation;
IUD: intrauterine device.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acar 1989 Results not separate for PID.
Andersson 1980 Quasi-RCT and not randomized to doxycycline.
Bartlett 1982 Not an RCT.
Berkeley 1986 Results not separate for PID.
Blanco 1983 Results not separate for PID.
Brihmer 1988 Did not report effectiveness or safety outcomes.
Brihmer 1989 Not a comparison of interest.
Group A: doxycycline 200 mg IV the first day, followed by 100 mg PO daily for 10 days + benzylpenicillin-
procaine 2.25 millions IM twice daily for 2 days
Group B: trimethoprim 160 mg + sulfamethoxazole 800 mg IV twice daily the first day, followed by 800 mg
PO for 10 days
Bruhat 1986 Not a comparison of interest.
Group A: sulbactam 2 g daily IV + ampicillin 4 g daily for 5 days, followed by 15 days of sulbactam IM +
ampicillin 2 g daily (n = 9)
Group B: cefoxitin 6 g daily IV for 5 days, followed by 15 days of cefoxitin 2 g daily IM (n = 11)
In both groups, if there was evidence of chlamydial infection, doxycycline 200 mg PO daily for 30 days given
Bruhat 1989 Not a comparison of interest.
Group A: sulbactam 2 g daily IV + ampicillin 4 g daily for 5 days, followed by 15 days of sulbactam IM +
ampicillin 2 g daily (n = 20)
Group B: cefoxitin 6 g daily IV for 5 days, followed by 15 days of cefoxitin 2 g daily IM (n = 20)
Bruno 1985 Not an RCT
Carty 1973 Not antibiotic
Chatwani 1997 Not a comparison of interest.
Group A: trospectomycin 500 mg IV every 8 h for at least 4 days of inpatient treatment and had achieved
complete resolution of sign and symptoms of acute PID, followed by 10 days of doxycycline PO (n = 26)
Group B: cefoxitin 2 g every 6 h + doxycycline 100 mg PO or IV for at least 4 days of inpatient treatment and
had achieved complete resolution of sign and symptoms of acute PID, followed by 10 days of doxycycline PO
(n = 13)
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Confino 1988 Did not report effectiveness or safety outcomes
De Beer 1983 Not a comparison of interest.
Group A: ampicillin 2 g IV on admission and then 1 g IV every 4 h thereafter. If the response was good,
ampicillin was administered PO after 48 h
Group B: cefoxitin 2 g IV followed by 1 g IV every 8 h. This was continued for at least 72 h
Drasa 2010 Results not separate for PID.
Drusano 1982 Results not separate for PID
Duarte 1995 Not an RCT.
Faro 1988 Not a comparison of interest.
Group A: ceftizoxime 2 g IV every 8 h for at least 5 days (n = 18)
Group B: cefotaxime 2 g IV every 8 h for at least 5 days (n = 19)
Fedele 1989 Not PID.
Frongillo 1992 Results not separate for PID.
Gall 1981 Not all participants randomized.
Gall 1990a Not an RCT.
Gall 1990b Not a comparison of interest.
Group A: clindamycin 900 mg + tobramycin 80 mg/m2 IV every 8 h for at least 4 days.
Group B: clindamycin 900 mg + placebo IV every 8 h for at least 4 days
Both treatment were followed by clindamycin 450 mg PO every 6 h, to complete 14 days of treatment
Gerber 1992 Not a comparison of interest.
Group A: oxytetracycline 4 × 0.5 g PO daily or doxycycline 2 × 0.1 g PO daily, initially IV + metronidazole
first 2 days 2 × 0.5 g IV from day 3, 2 × 0.25 g PO daily)
Group B: oxytetracycline 4 × 0.5 g PO daily or doxycycline 2 × 0.1 g PO daily, initially IV + metronidazole
first 2 days 2 × 0.5 g IV from day 3, 2 × 0.25 g PO daily) + additional bathing therapy
Group C: amoxicillin-clavulanic acid 1st + 2nd day 1.2 g daily IV, 3rd to 10th day 3 × 0.75 g PO daily
Group D: ciprofloxacin initial 2 × 0.2 g IV then to day 10 2 × 0.5 g PO daily + metronidazole 1st and 2nd
day 2 × 0.5 g day IV from day 3, 2 × 0.25 g PO daily
Gerstner 1990 Results not separate for PID.
Ghomian 2012 Many inconsistencies in the study, author did not respond.
Giamarellou 1982 Results not separate for PID.
Gibbs 1980a Not a comparison of interest.
Group A: penicillin G 5 x 106 units IV every 6 h + kanamycin 500 mg IM every 12 h for 4-7 days after good
clinical response (n = 5)
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Group B: spectinomycin 500 mg IM every 12 h for 4-7 days after good clinical response (n = 7)
Gjonnaess 1981 Not all participants randomized.
Grafford 1980 Not a comparison of interest.
Group A: bacampicillin 400 mg PO 3 times daily for 14 days (n = 39).
Group B: bacampicillin 800 mg PO 3 times daily for 14 days (n = 31).
Grafford 1981 Not an RCT.
Gunning 1986a Not a comparison of interest.
Group A: piperacillin 250 mg/kg daily IV divided into every 6 h for 5-11 days (n = 31)
Group B: clindamycin 600 mg IV 6/6 h + gentamicin 1.5 mg/kg IV every 8 h for 3-8 days (n = 33)
Gunning 1986b Not a comparison of interest.
Group A: sulbactam 1 g + ampicillin 2 g IV every 6 h until asymptomatic and without clinical signs or pathogen
sensitivity testing dictated a change in therapy (n = 21)
Group B: clindamycin 600 mg IV 6/6 h + gentamicin 1.5 mg/kg IV every 8 h until asymptomatic and without
clinical signs or pathogen sensitivity testing dictated a change in therapy (n = 18)
Hager 1989 Not PID.
Harding 1982 Not PID.
Harding 1984 Not PID.
Hemsell 1982 Results not separate for PID.
Hemsell 1987 Not an RCT.
Hemsell 1988a Authors report data without details of clinical cure
Hemsell 1988b Results not separate for PID.
Hemsell 1988c Not a comparison of interest.
Group A: cefoxitin 2 g IV every 6 h + doxycycline 100 mg every 12 h for minimum of 4 days and for at least
48 h after defervescence, followed by doxycycline 100 mg PO when discharged from the hospital to complete
14 days of therapy (n = 32)
Group B: ceftizoxime 2 g IV every 12 h + doxycycline 100 mg was given separately in 250 mL diluent and
infused over 2 h for minimum of 4 days and for at least 48 h after defervescence, followed by doxycycline 100
mg PO when discharged from the hospital to complete 14 days of therapy (n = 30)
Group C: ceftizoxime 2 g IV 3 times daily every 8 h for minimum of 4 days and for at least 48 h after
defervescence (n = 29)
Group D: ceftizoxime 2 g IV twice daily every 12 h for minimum of 4 days and for at least 48 h after
defervescence (n = 30)
Hemsell 1988d Results not separate for PID.
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Hemsell 1990 Not a comparison of interest.
Group A: ampicillin 2 g + sulbactam 1 g IV every 6 h.Women whose treatment was successful received therapy
for a mean (± SD) of 4.5 ± 0.9 days (n = 35)
Group B: cefoxitin 2 g IV every 6 h. Women whose treatment was successful received therapy for a mean (±
SD) of 4.5 ± 0.9 days (n = 19)
Hemsell 1991 Did not report effectiveness or safety outcomes.
Hemsell 1993 Not a comparison of interest.
Group A: ampicillin/sulbactam 3 g IV every 6 h on at least 4 consecutive days and until the woman was afebrile
for at least 48 h. Women with C trachomatis at study entry received doxycycline 100 mg PO twice daily for 10-
14 days when discharged from hospital. Women negative for C trachomatis discharged on no oral antibiotic (n
= 76).
Group B: cefoxitin 2 g IV every 6 h on at least 4 consecutive days and until the woman was afebrile for at least
48 h. Women with C trachomatis at study entry received doxycycline 100 mg PO twice daily for 10-14 days
when discharged from hospital. Women negative for C trachomatis discharged on no oral antibiotic (n = 41).
Hemsell 1997 Not a comparison of interest.
Group A: meropenem 500 mg IV given over 20-30 minutes every 8 h for at least 48 h, for clinical evaluation
(suggested treatment duration 4-10 days, with a maximum duration of 28 days)
Group B: clindamycin 900 mg IV + gentamicin 1.5 mg/kg following a loading dose of 2.0 mg/kg every 8 h
for at least 48 h, for clinical evaluation (suggested treatment duration 4-10 days, with a maximum duration of
28 days)
Henry 1985 Not a comparison of interest.
Group A: aztreonam 1-2 g every 8-12 h. Most women received 1 or 2 g 3 times daily. Clindamycin (usually
at a dosage of 600 mg every 8 h) administered concurrently with aztreonam as a means of providing coverage
against Gram-positive and anaerobic organisms (n = 50; 5 with PID)
Group B: gentamicin 3-5 mg/kg daily in 3 equally divided doses + clindamycin 600 mg every 8 h (n = 38; 8
with PID)
In both groups, antibiotics usually administered IM or IV; however, PO administration of clindamycin was
permitted
Holloway 1988 Results not separate for PID.
Ibrahim 1990 Not a comparison of interest.
Group A: amikacin 14mg/kg IV infusion in 150 mL saline over 30minutes once daily. Treatment administered
for 7-9 days
GroupB: amikacin 14mg/kg IV infusion in 150mL saline over 30minutes twice daily. Treatment administered
for 7-9 days
Group C: netilmicin 6.6 mg/kg IV infusion in 150 mL saline over 30 minutes once daily. Treatment admin-
istered for 7-9 days
Group D: netilmicin 6.6 mg/kg IV infusion in 150 mL saline over 30 minutes 3 times daily. Treatment
administered for 7-9 days
All 4 groups also received tinidazole 0.8 g once daily + ampicillin 4 g daily
Jemsek 1997 Not a comparison of interest.
Group A: minimum 12 doses = 3 days of ampicillin 2 g/sulbactam 1 g IV every 6 h
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Group B:minimum 12 doses = 3 days of cefoxitin 2 g IV every 6 h.
Doxycycline 100 mg PO or IV twice daily administered concurrently to women with cultures positive for
C trachomatis. Because of the significant possibility of false negatives, women with cultures negative for C
trachomatis were empirically treated with 10-14 days of doxycycline 100 mg PO twice daily after the study
ended
Jordheim 1974 Not a comparison of interest.
Group A: pivampicillin 175 mg PO capsule 4 times daily for 0-4/5-9/10-14/15-19 days (n = 28)
Group B: pivampicillin 350 mg PO capsule 4 times daily for 0-4/5-9/10-14/15-19 days (n = 30)
In some cases, duration of therapy was longer or shorter depending on clinical response
Judlin 1995 Not a comparison of interest.
Group A: ofloxacin 400 mg daily in 2 × 200 mg tablets morning and night; amoxicillin-clavulanic acid 2 g
daily, 2 × 500 mg tablets morning and night. Combination given for 3 weeks.
Group B: doxycycline 200 mg daily, 1 × 100 mg tablet morning and night; amoxicillin-clavulanic acid 2 g
daily, 2 × 500 mg tablets morning and night. Combination given for 6 weeks
Knupell 1988 Not a comparison of interest.
Group A: cefotetan 2 g IV every 12 h, mean duration of therapy 6.1 days (n = 36)
Group B: cefoxitin 2 g IV every 6 or 8 h, mean duration of therapy 6.4 days (n = 17)
Kosseim 1991 Not a comparison of interest.
Group A: ampicillin-sulbactam 750 mg PO twice daily for 10 days (n = 38)
Group B: cefoxitin 2 g IM + probenecid 1 g PO, followed by doxycycline 100 mg twice daily for 10 days (n
= 37)
Kotoulas 1992 Not an RCT.
Kunzig 1990 Results not separate for PID.
Kvile 1980 Compared same drug with different doses.
Larsen 1986 Results not separate for PID.
Larsen 1992 Not a comparison of interest.
Group A: imipenem-cilastatin 500 mg IV every 6 or 8 h. Treatment continued for at least 3 days or until the
woman was afebrile for 24-48 h (n = 44)
Group B: clindamycin 900 mg IV every 8 h + gentamicin 1.5 mg/kg IV or IM for first dose, and 1.0 mg/kg
every 8 h for succeeding doses. Treatment continued for at least 3 days or until the woman had been afebrile
for 24-48 h (n = 50)
In both treatments, if therapy for Chlamydia spp was indicated, doxycycline 100 mg PO or IV added to either
regimen every 12 h
Livengood 1992 Not a comparison of interest.
Group A: clindamycin 600 mg IV every 6 h + cefamandole 2 g every 6 h
Group B: clindamycin 600 mg IV every 6 h + doxycycline 100 mg + 10 mL of 4% sodium bicarbonate
alternating with placebo (5% dextrose in water) every 6 h
Protocol antibiotic therapy continued for 48 h after declaration of response and for minimum of 5 days (20
doses), after which women discharge without supplemental oral antibiotic treatment
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Ma 2010 Not a comparison of interest.
Group A: levornidazole 0.5 g twice daily for 5-7 days.
Group B: ornidazole 0.5 g twice daily for 5-7 days.
Maggioni 1998 Results not separate for PID.
Maki 1979 Not PID.
Mandell 1993 Results not separate for PID.
Marier 1982 Not a comparison of interest.
Group A: piperacillin 250 mg/kg daily IV every 4-6 h.
Group B: carbenicillin 450 mg/kg daily IV every 4-6 h.
Marshall 1982 Not PID.
Matsuda 1988 Not a comparison of interest.
GroupA: cefpodoxime proxetil 100mg tablet + dummy bacampicillin placebo, twice daily. Alternately, dummy
CS-807 + dummy bacampicillin, twice daily; therefore, women took tablets 4 times daily for 7 consecutive
days
Group B: bacampicillin 250 mg tablet + dummy cefpodoxime proxetil placebo, 4 times daily for 7 consecutive
days
Matsuda 1989 Not a comparison of interest.
Group A: ceftibuten 100 mg 3 times daily. The shape of 2 tablets (7432-S, bacampicillin) was different, so
women took 8 tablets daily (after meal and before sleep) with placebo. At least 3-day administration when a
primary physician found cure of the infection, or assessed no efficacy and need to change a different drug
Group B: bacampicillin 250 mg 4 times daily. The shape of 2 tablets (7432-S, bacampicillin) was different,
so women took 8 tablets daily (after meal and before sleep) with placebo. At least 3-day administration when
a primary physician found cure of the infection, or assessed no efficacy and need to change a different drug
Moghtadaei 2008a Risk of fraud, no reply from author.
Moghtadaei 2008b Risk of fraud, no reply from author.
Ness 2002 Compared the same drugs as inpatient versus outpatient.
Ness 2005 Not a comparison of interest.
Group A: inpatient strategy cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV or PO twice daily for at least
72 h, followed by doxycycline 100 mg PO twice daily for a total 14-day course
Group B: outpatient treatment consisted of cefoxitin 2 g IM + probenecid 1 g PO, followed by doxycycline
100 mg PO twice daily for 14 days
Nicolle 1986 Not PID.
Paavonen 1985 Did not report effectiveness or safety outcomes.
Pastorek 1985 Results not separate for PID.
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Roy 1998 Not PID.
Ruiz Conde 1999 Results not separate for PID.
Sanfilippo 1989 Not a comparison of interest.
Group A:mezlocillin 250 mg daily every 6 h + appropriate IV solution containing no antibiotic but identical
in appearance to tobramycin solution every 8 h
Group B: aqueous crystalline penicillin G 480,000 U/kg every 6 h (maximum of 20 million units daily) +
tobramycin 3 mg/kg daily every 8 h. Dose of tobramycin was then adjusted according to peak and rough blood
levels to keep tobramycin levels within therapeutic range. Another physician, not directly involved with clinical
management, evaluated tobramycin levels and contacted the pharmacy for changes of tobramycin levels
Schnider 1979 Not a comparison of interest.
Group A: penicillin G 30 million units daily + netilmicin 2 mg/kg daily parenterally over 5 days
Group B: penicillin G 30 million units daily + gentamicin 3 mg/kg daily parenterally over 5 days
Senft 1986 Results not separate for PID.
Sesti 1990 Not an RCT.
Sharma 2007 Not a comparison of interest.
Group A: ofloxacin 400 mg/ornidazole 500 mg/Saccharomyces boulardii (2 million spores)/lactic acid bacillus
(60 million spores)/serratiopeptidase 10 mg once daily for total of 10 days (n = 98)
Group B: doxycycline 100 mg twice daily + metronidazole 400 mg 3 times daily + serratiopeptidase 10 mg
once daily for total of 10 days (n = 95)
Silva 1990 Results not separate for PID.
Skerk 2003 Compared same drug with different doses.
Spence 1981 Not a comparison of interest.
Group A: ampicillin 2 g IV every 4 h for minimum of 96 h followed by 0.5 g PO every 6 h to complete 10
days of treatment
Group B: doxycycline 200 mg IV initially, then 100 mg IV every 12 h for at least 96 h followed by 100 mg
PO every 12 h to complete 10 days of treatment
Stamm 1984 Not PID.
Stiglmayer 1996 Not a comparison of interest.
Group A: sulbactam 1 g + ampicillin 2 g IV every 8 h.
Group B: cefoxitin 2 g IV every 8 h.
Sweet 1988 Not a comparison of interest.
Group A: cefotetan 2 g IV every 12 h + doxycycline 100 mg IV every 12 h
Group B: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h
Both treatments had a minimum of 4 days, at least for 48 h after disappearance of fever, after hospital discharge,
doxycycline 100 mg PO every 12 h to complete 14 days of treatment
102Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Sweet 1994 Results not separate for PID.
Takase 1986 Not a comparison of interest.
Group A: ofloxacin 1 dose 200 mg 3 times daily for 7 days.
Group B: amoxicillin 1 dose 250 mg 4 times daily for 7 days.
Tellado 2002a Not an RCT.
Tellado 2002b Not an RCT.
Teppler 2002 Not an RCT.
Thompson 1980 Not a comparison of interest.
Group A: aqueous penicillin G, 5 million units IV every 4 h + gentamicin 60 mg or 80 mg IV every 8 h based
on weight
Group B: amoxicillin 1 g PO every 4 h.
If the woman could not take oral medicines she received ampicillin 1 g IV every 4 h, until she could be
changed to oral amoxicillin. She was switched as soon as possible to ampicillin 2 g PO daily if on regimen A,
or amoxicillin 2 g PO daily if on regimen B, to complete 10 consecutive days of antibiotic treatment
Thompson 1985 Not a comparison of interest.
Group A: aqueous procaine penicillin G, 4.8 million units IM + probenecid 1 g PO, followed by ampicillin
monohydrate 0.5 g PO 4 times daily for 10 days
Group B: tetracycline hydrochloride 1.5 g PO as a single loading dose, followed by tetracycline 0.5 g PO 4
times daily for 10 days
Tulkens 1988 Not a comparison of interest.
Group A: netilmicin 6.6 mg/kg IV once daily + tinidazole 0.8 g daily (once daily) + ampicillin 4 g daily (twice
daily) for mean duration of 7 days
Group B: netilmicin 2.2 mg/kg IV 3 times daily + tinidazole 0.8 g daily (once daily) + ampicillin 4 g daily
(twice daily) for a mean duration of 7 days
Tulkens 1991 Not an RCT.
Van Gelderen 1987 Not a comparison of interest.
Group A: ceftriaxone 2 g IV once daily for 2 days followed by 1 g once daily for the next 2-8 days
Group B: penicillin G sodium 4200 mg IV + chloramphenicol 500 mg 4 times daily for 4-10 days
Additional treatment: because there was a strong suspicion that anaerobic bacteria (which were not isolated
specifically) were present, 5 ceftriaxone-treated women and 8 penicillin/chloramphenicol-treated women also
received nitroimidazole 400-500 mg every 8 h
Walker 1991 Not a comparison of interest.
Group A: cefotetan 2 g IV every 12 h + doxycycline 100 mg IV every 12 h for minimum of 4 days and for at
least 48 h after clinical response, followed by doxycycline 100 mg PO every 12 h was continued to complete a
14-day course after the woman was discharged (n = 54)
Group B: cefoxitin 2 g IV every 6 h + doxycycline 100 mg IV every 12 h for minimum of 4 days and for at
least 48 h after clinical response, followed by doxycycline 100 mg PO every 12 h was continued to complete a
14-day course after the woman was discharged (n = 54)
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Wikler 1989 Not a comparison of interest.
Group A: ceftizoxime 2 g every 12 h.
Group B: ceftizoxime 2 g every 8 h.
Group C: ceftizoxime 2 g + doxycycline 100 mg every 12 h.
Group D: cefoxitin 2 g every 6 h + doxycycline 100 mg every 12 h.
Women receiving IV doxycycline continued to receive doxycycline 100 mg PO every 12 h after discharge from
hospital for a total duration of 14 days (IV + PO therapy)
Witte 1993 Not a comparison of interest.
Group A: pefloxacin 800 mg daily + metronidazole 500 mg every 8 h.
Group B: doxycycline initial dose of 200 mg followed by 100 mg daily + metronidazole 500 mg every 8 h
For both group A and B, the duration of treatment was at least 10 days, and maximal 14 days, unless the
clinical response was considered insufficient after 5 days. The minimal duration of therapy to allow efficacy
assessment was 5 days
Wynd 1999 Cost-effectiveness study comparing ampicillin/sulbactam versus cefoxitin for the treatment of PID
h: hour; IM: intramuscular; IV: intravenous; PID: pelvic inflammatory disease; PO: per os; RCT: randomized controlled trial; SD:
standard deviation.
Characteristics of ongoing studies [ordered by study ID]
Wiesenfeld 2015
Trial name or title The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
Methods Randomized placebo-controlled trial comparing 2 antibiotic treatment regimens for acute PID: group A:
ceftriaxone + doxycycline; group B: ceftriaxone + doxycycline + metronidazole for 14 days
Participants Women aged 15-40 years.
Interventions Group A: ceftriaxone 250 mg IM single dose + doxycycline 100 mg PO twice daily × 14 days + placebo PO
twice daily × 14 days
Group B: ceftriaxone 250 mg IM single dose + doxycycline 100 mg PO twice daily × 14 days + metronidazole
500 mg PO twice daily × 14 days
Outcomes Clearance of anaerobic organisms from the endometrium (over 30 days) (designated as safety issue: no)
Follow-up: 1 month for clinical outcomes, and assessment for clearance of microorganisms from the upper
genital tract
Starting date November 2010.
Contact information Harold Wiesenfeld, Associate Professor, University of Pittsburgh
Notes
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IM: intramuscular; PID: pelvic inflammatory disease; PO: per os.
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D A T A A N D A N A L Y S E S
Comparison 1. Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness of cure in mild-
moderate PID
2 243 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.89, 1.55]
2 Sensitivity analysis by risk of
bias: effectiveness of cure in
mild-moderate PID
1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.10, 1.67]
3 Effectiveness of cure in severe
PID
1 309 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.96, 1.05]
4 Any antibiotic-related
adverse effect leading to
discontinuation use of
macrolide versus tetracycline
3 552 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.38, 1.34]
Comparison 2. Regimens containing quinolones versus cephalosporins
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness of cure in mild-
moderate PID
3 459 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
2 Effectiveness of cure in severe
PID
2 313 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.23]
3 Any antibiotic-related
adverse effect leading to
discontinuation cephalosporin
versus quinolone
5 772 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [0.52, 9.72]
Comparison 3. Regimens containing nitroimidazoles versus no nitroimidazoles
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness of cure in mild-
moderate PID
5 2427 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.93, 1.10]
2 Sensitivity analysis by risk of
bias: effectiveness of cure in
mild-moderate PID
2 1201 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.98, 1.15]
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3 Effectiveness of cure in severe
PID
11 1383 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.92, 1.01]
4 Any antibiotic-related
adverse effect leading to
discontinuation
16 3788 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.63, 1.59]
Comparison 4. Regimens containing clindamycin plus aminoglycoside versus quinolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness of cure in mild-
moderate PID
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.69, 1.13]
2 Effectiveness of cure in severe
PID
2 151 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.87, 1.19]
3 Any antibiotic-related
adverse effect leading to
discontinuation
3 163 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.02, 1.72]
Comparison 5. Regimens containing clindamycin plus aminoglycoside versus cephalosporin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Effectiveness of cure in mild-
moderate PID
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.95, 1.09]
2 Effectiveness of cure in severe
PID
10 959 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.06]
3 Any antibiotic-related
adverse effect leading to
discontinuation
10 1172 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.18, 3.42]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following changes to the protocol dated from 5 September 2013.
Criteria for considering studies
Types of interventions
In our protocol, we stated: “Trials comparing any antibiotics regimen compared to an alternative regimen or placebo will be eligible
for inclusion.”
After a long debate involving discussion with editorial board and reviewers, we decided to focus on the most clinically relevant
interventions and comparisons; as identified in current clinical guidelines for treatment of PID.
Types of outcomes
The protocol listed a secondary outcome of “If the percentage of pain is available, a treatment will be considered effective when the
reduction is 50% or more.” However, from the clinical point of view, a reduction of pain over 50% is not relevant. For instance, if a
woman with PID has an initial pain level of 10 and after treatment, the pain level was 4, this woman had a 60% reduction. However,
in another case, a women with PID had an initial pain level of 5, and after treatment, her pain level was 3. In these two cases, if the
50% reduction in pain score criteria was used, the first woman would have obtained clinical cure while the second woman would not,
despite the second woman having a lower pain level. Therefore, we did not perform this analysis, and used the clinical cure according
to the criteria defined by the treating physician (e.g. resolution or improvement of signs and symptoms related to PID).
We amended the wording under secondary outcomes to clarify that where studies reported multiple time points, we considered the
period between 14 and 28 days after initiation of treatment.
Search
In our protocol, we planned that searches would be updated within six months of publication in the review. Due to a lengthy publication
process, we have extended this to 12 months
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Data collection and analysis
Data extraction and management
In our protocol, we did not plan to conduct separate analyses for differing severity of disease. However, while preparing our review, we
determined that severe PID (i.e. with tubo-ovarian abscess) is a distinct condition from mild-moderate PID (i.e. without tubo-ovarian
abscess). Therefore, we decided to present separate analyses for these two groups.
Statistical model
The protocol planned fixed-effect models. However, we decided to use a random-effects model where analyses had substantial hetero-
geneity (I2 40% or greater), to present a more conservative effect estimate.
Effect measure
We stated in the protocol that we would calculate Peto odds ratios for dichotomous outcomes. However, we noted that the Cochrane
Handbook for Systematic Reviews of Interventions suggests avoiding using the Peto method as a default method of analysis because it may
cause bias unless events are not particularly common and there are similar numbers in the intervention and control groups (Higgins
2011). As these criteria were not fulfilled in the review, we therefore, used Mantel-Haenszel risk ratios for all dichotomous outcomes,
Subgroup analysis
In our protocol, we planned to undertake a subgroup analysis by PID severity, but in view of our decision to present separate analyses
for mild-moderate and severe PID, the subgroup analysis was no longer appropriate.
Sensitivity analyses
In our protocol, we planned to undertake sensitivity analyses for the following factors: risk of bias, heterogeneity (I2 40% or greater),
length of time to measurement of outcomes, and method of PID diagnosis.
In the review, we listed variables that would be used to explore heterogeneity under the heading “Investigation of heterogeneity”, and
we included length of time to outcome measurement and method of PID diagnosis as two of these variables.
For the sensitivity analysis by risk of bias, we added a definition of low risk of bias (which we defined as blinded, and at low risk of
selection bias).
Quality assessment
We added the reporting of quality of evidence following MECIR guidelines.
N O T E S
109Antibiotic therapy for pelvic inflammatory disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
